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Abstract
Schizophrenia, aging, and medication factors combine to present a very complex clinical
presentation in caring for the elderly population with schizophrenia. The aging body
displays a slowing of physiological processes, which alters the pharmacokinetics and
pharmacodynamics of medications prescribed. Multiple comorbid health factors and the
medications recommended for treatment may become detrimental to the overall body
health, causing more problems for the older individual. This evidence based practice
project reviewed literature and evidence to focus on the question, “In community
dwelling older adults with schizophrenia, what is best practice for antipsychotic
medication management?” The literature search resulted in classifying 16 articles as
relevant to medication management in older adults with schizophrenia. The results of this
project were limited by the paucity of available quality research material on the subject.
Few studies were inclusive of the 65-years and older population. However, the literature
analysis resulted in several recommendations to guide decision-making and promote the
safe incorporation of antipsychotic medications in the plan of care to treat schizophrenia
in older patients. These may be used by Psychiatric-Mental Health Nurse Practitioners in
the clinical reasoning process.
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Chapter 1 Introduction
Schizophrenia is on the rise among the elderly in the United States. The
prevalence of schizophrenia in people age 65 and over is 0.5% of the total population
(Reeves et al., 2011). With the impact of medical advances through research, life
expectancy is projected to continue its upward trend (“Explaining divergent,” 2011). This
results in the population of elderly schizophrenic patients doubling over the next two
decades. Mental health practitioners will be caring for the greater proportion of these
older patients in mental health clinics. Preparations are necessary to plan for the best care
focusing on this special population and their unique needs.
Schizophrenia is a chronic mental health problem characterized by a mixture of
positive and negative symptoms. Positive symptoms include excess or distortions of
thought content, perception, language, thought processing, and self-monitoring. Negative
symptoms are restrictions in range and intensity of emotion, fluency and productivity of
thought and speech, and initiation of goal-directed behavior. For the diagnosis to be
made these symptoms must be present for the majority of one month or some persisting
symptoms should be present at least six months. These symptoms are associated with
marked social or occupational dysfunction as well as a range of cognitive, emotional and
communication dysfunction (“Schizophrenia,” n.d.). Schizophrenia is usually diagnosed
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between the ages of 10 to 25 years for men and 25 to 35 years for women (Sadock &
Sadock, 2007). These individuals can expect a lifetime of challenges including unmet
health care needs, lessened quality of life and higher mortality rates (Saha, Chant, &
McGrath, 2007).
As with the general population, the number of older adults with schizophrenia is
increasing. Currently there are 2.2 million Americans suffering from schizophrenia
(Reeves et al., 2011). The disease and aging factors combine to present a very complex
situation for the context of care and action and side effects of drugs. The clinical picture
is confounded by multiple medical comorbidities, physiological changes of aging,
polypharmacy issues, and alcohol and substance abuse. This chapter examines these
factors, describes the synergy among them complicating medication management, and
presents the evidence-based practice (EBP) question with definitions. This evidencebased project’s focus is safe and effective medication management for the aging
population with schizophrenia.
Background and Significance
The core symptoms of schizophrenia arise from dysfunction in many areas of the
brain. Effective treatment involves targeted medication therapy aimed at the specific
areas of the brain involved. Timely treatment may prevent or delay the full-syndrome
onset of schizophrenia (Miller, 2009). Studies of schizophrenia in the elderly population
suggest that consistency of treatment and medication are a predictor of successful
symptom management (Sapra, Vahia, Reyes, Ramirez, & Cohen, 2008; Farley, Wang,
Hansen, Voils, & Maciejewski, 2011). Currently clinicians are aware that older adults
with schizophrenia have complicated management issues because of the multiple levels
2

of medication necessary to care for the spectrum of health needs including both mental
and physiological illnesses commonly associated with aging. Unless a best practice
approach is used, this predicted load on the mental health system into the next decade
will result in more adverse physical health problems.
Context of Care
A majority of the elderly population with schizophrenia today dually is eligible to
receive both Medicare and Medicaid. Medicare has been further divided into Part A
(hospital insurance coverage), Part B (medical provider insurance coverage), and Part D
(prescription drug coverage). Medicare Part D is available from multiple insurance
companies that offer a variety of coverage dependent on patient preference. Medicaid is
a jointly funded state and federal funding health care for low income and disabled
individuals (“Eligibility,” n.d.). Appropriate medication management is made more
difficult within the government systems because of fragmented mental health care, fewer
trained providers, complicated and restrictive insurance management, decreasing funding,
and increased caseloads.
Fragmentation of care. Due to shortages in the community of health care
professionals trained to provide safe and effective care for older people with
schizophrenia, medical problems often go unnoticed or are misdiagnosed (Bartels, 2004).
It is estimated that one half of this population have co-occurring medical and substance
abuse disorders, and almost half of these disorders are either not diagnosed or are
inappropriately treated (Rosenberg, Woo, & Roane, 2009). Medical clinics are not
equipped to manage the care of patients with chronic severe mental illnesses because of
the complexities of psychiatric issues. Mental health clinics only focus on the psychiatric
3

issues. Additionally, physical illnesses and early signs of physical or emotional problems
are often incorrectly assumed to be part of the delusional symptoms of the mental illness
(Csernansky, 2002). This misdiagnosis delays the onset of effective treatment, which
may in turn lead to severe or life-threatening conditions. Dementia symptoms may also
be misinterpreted as a part of the psychiatric presentation resulting in inappropriately
prescribed or adjusted medications (Csernansky, 2002). This fragmentation of care is
only one pressing concern.
Fewer trained providers. Most elderly patients with schizophrenia receive the
majority of their psychiatric care from local mental health centers in the community. As
funding cuts occur in each state, the amount of money supporting mental health treatment
has decreased. Funding for schools with mental health nurse practitioner curricula has
also decreased, resulting in the closure or suspension of many programs and declining
numbers of providers entering the workforce. This lack of support leaves fewer trained
providers with specialization in mental health to staff the community centers to care for
the needs of the population with schizophrenia. Patients also often lack support to
navigate the insurance system.
Complicated and restrictive insurance. The healthcare system makes acquiring
the necessary medication complicated for the provider as well as the elderly patient with
schizophrenia. Medicare insurance has a limited formulary and protocol that must be
followed by prescribers that still may result in denial or less than full coverage for
antipsychotic medications. When the newest medications gain Food and Drug
Administration (FDA) approval, the co-pay often results in a higher level of coverage
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requiring more personal outlay of money. Although these drugs may be better tolerated
with fewer side effects, thereby desired for this patient population, the cost is prohibitive.
Even if Medicare approves a drug, acquiring the medication is still fraught with
additional system problems. Quantities of prescribed medications could be limited to 30
pills a month making a preferred multiple dosing per day protocol problematic.
Recommendations made to prescribers by the insurance company for alternative choices
of drugs, or tiers, are often not suitable for the elderly patient with schizophrenia because
of negative side effects. Practitioners may be directed to follow step therapy requiring
the patients documented history of failed attempts on other drugs preferred by the
insurance company to be filed in a lengthy review. This process takes precious time
away from patient care and delays the introduction of needed medication that will
alleviate suffering and eliminate symptoms.
Economic challenges. A monthly Supplemental Security Income (SSI) check,
intended to support a base subsistence, is provided to the elderly person with
schizophrenia at age 65 years old or prior if disability was determined. The average SSI
monthly check in 2013 was $423.02 with 2,092,000 recipients. Of this group, 919,000
received this SSI as their only support (“Monthly statistical,” 2013). This meager amount
must be used to pay for all supplemental costs of healthcare as well as living expenses.
Following up with all providers and paying Medicare Part D costs for drug coverage both
pose additional financial strain on already tight budgets.
Additionally, many provider practices want co-payment for service. This is not
easily affordable to a population also struggling to pay for medications prescribed for
treatment. With multiple providers, the costs can be compounded by each specialist
5

attending to the needs of the elderly patient with schizophrenia. Once Medicare Part D
has paid for a preset maximum amount, the patient must pay “out of pocket” until a
maximum amount is paid which is sometimes thousands of dollars. This is referred to as
the “donut hole” of coverage. The Affordable Care Act (ACA) is scheduled to gradually
reduce the amount of co-payment and percentage of “out of pocket” expense through
2020. In 2013, the ACA offered the elderly a 52.5% discount on name brand drugs and a
21% discount for generic drugs (Kaplan, 2011). Incremental decreases over the next
seven years will be small and slow leading to an end point of 25% responsibility for both
generic and name brand name drugs in 2020 and a $903 annual cost as the enrollee’s
responsibility (Kaplan, 2011).
Alternative options for patients to acquire the necessary medication for treatment
of schizophrenia are few, despite the potential risks to self and others when individuals
receive inadequate treatment. The patient must rely on samples or patient assistance
programs designed by the drug companies to assist during this “donut hole” of coverage.
With the increased cost, elderly patients with schizophrenia often economize by taking
the medication less often than ordered or not filling the prescription. This irregular or
absent dose may lead to decompensation with psychosis, instability, and potential harm to
these elderly patients. Utilization of emergency services, admissions to acute care
hospitals, and interventions resulting from this destabilization further increase the cost of
mental health. Cost concerns are also often compounded with the issue of limited
providers.
Limited providers. Methods used to manage resources include limiting
reimbursements to providers for services and placing restrictions on prescribing practices
6

for medications. The percentage of Medicare patients per practice is capped in many
offices to buffer the overall decreased repayment for care paid by this plan. This reduced
Medicare reimbursement provides a disincentive for providers to accept new geriatric
patients (Rosenberg et al., 2009). These issues, along with the lack of knowledgeable
providers willing to negotiate and maintain both the medical and psychiatric needs of this
elderly population, are some of the flaws of the healthcare system that severely impact
the care options of the elderly population with schizophrenia. Having examined the
complicated context in which elderly patients with schizophrenia seek care, the actions
and side effects of psychopharmacology follows.
Actions and Side Effects of Drugs
Just as the health care context is complex, so too are the action and side effects of
antipsychotic drugs. Psychopharmacological intervention involves modulation of
multiple neurotransmitters aimed at a remission of symptoms of schizophrenia. These
antipsychotic drugs are known to be “the most complex pharmacological mechanisms of
any drug class in the field” (Stahl, 2008, p. 328). Prescribing practice for the older
population with schizophrenia is focused on identifying the specific neural pathways of
the brain to target treatment for optimum symptom management with minimum side
effect potential. Table 1.1 reviews the major neural pathways affected by the most
commonly prescribed antipsychotic in each class of medications prescribed for the older
population with schizophrenia.
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Table 1.1
Neural Pathways and Side Effects of Antipsychotic Drug Classes
Drugs by Class
• Typical
(Conventional)

Neural Pathways Effected

Common Side Effects

• Alpha – 1

• Dizziness, drowsiness, and
decreased blood pressure.

• Dopamine- (D2 antagonist)

• Apathy, lack of motivation,
anhedonic, movement disorders,
and elevated prolactin
(galactorrhea, amenorrhea,
demineralization of bones, weight
gain).

• Histamine (H1)

• Weight gain, drowsiness.

• Muscarinic (M1)

• Constipation, blurred vision, dry
mouth, and drowsiness.

• Atypical

• Serotonin Dopamine
• Weight gain
Antagonists*
• Dyslipidemia
• D2 antagonists with rapid
• Diabetic risks
disassociation*
• Anxiety
• Serotonin -Dopamine Partial • Prolonged QT interval
Agonist*
• Elevated prolactin levels
• Serotonin partial agonist at
• EPS
5HT1A receptor*
• Sedation
Note. Adapted from Stahl’s essential psychopharmacology: Neuroscientific basis and
practical applications (3rd ed.), by S. M. Stahl, 2008, p. 342.
* The pharmacologic methods that serotonin and dopamine interact within the D2
receptor to elicit the desired antipsychotic effect are found in these four types of agonist.
They are unique to the atypical psychodynamic profile.
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Schizophrenia is a disorder affecting many areas of functioning including
cognitive, affective, negative, positive, and aggressive symptoms (see Figure 1.1). It is
difficult to envision one medication effectively treating all these areas (Stahl, 2008). The
five-dopamine pathways and symptoms associated with each are illustrated in Figure 1.1.

Figure 1.1 Schizophrenia model of dopamine output. Adapted from Stahl’s essential
psychopharmacology: Neuroscientific basis and practical applications (3rd ed.) by S.M.
Stahl, 2008, p. 262.
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Antipsychotic medications are responsible for a higher risk potential of major side
effects in the elderly population with schizophrenia. The cause of side effects in some
cases is known, as in the case of movement disorders associated with dopamine
antagonism in the nigrostriatal dopamine track (Leon et al., 2010). However, for some
side effects the cause is not known. These include causes of neuroleptic malignant
syndrome (NMS) as well as sudden cardiac death and strokes (Novick, Haro, Bertsch &
Haddad, 2010). Table 1.2 highlights the movement disorders and symptoms of each.
Movement disorders, also called pseudo-Parkinsonian symptoms, can be
classified in two types: extrapyramidal symptoms (EPS) and tardive dyskinesia (TD).
EPS includes a variety of symptoms characterized by changes in muscle tone, poverty of
voluntary movements (akinesia) or abnormal involuntary movements (dyskinesia). EPS
is associated with both conventional (typical) and atypical antipsychotic medication
administration. Symptoms may be acute or chronic, or delayed as in TD. Their presence
may spontaneously resolve or be permanent.
Tardive dyskinesia is a disorder of involuntary repetitive body movements that
can be delayed or slow in onset, which appears after high dose use of antipsychotics
(Lieberman & Tasman, 2006). Aging of the brain decreases dopamine functioning in the
corticostriatal pathway causing an increased prevalence of both extrapyramidal
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Table 1.2
Antipsychotic Drug Side Effects
Name
• Movement Disorders

• Neuroleptic
Malignant Syndrome

Category

Symptoms

• Extrapyramidal Symptoms

• Change in muscle tone,
poverty of voluntary
movements (akinesia),
abnormal involuntary
movements (dyskinesia)

• Tardive Dyskinesia

• Involuntary repetitive body
movements: Grimacing,
tongue protrusion &
movements, lip smacking,
puckering or protrusion, rapid
eye blinking, grunting, tics
and/or movements of limbs,
torso, or fingers.

• Neurological

• Life threatening disorder:
Rigidity, autonomic
instability, altered level of
consciousness and
hyperthermia, elevated
creatine, kinase, and
leukocytosis

Note. Adapted from “Incidence of extrapyramidal symptoms and tardive dyskinesia in
schizophrenia” by D. Novick, J. Haro, J. Bertsch, and P. Haddad, 2010, Journal of
Clinical Psychopharmacology, 30(5), pp. 531-540.
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symptoms and tardive dyskinesia (Meyers & Jeste, 2010). As a result, TD and EPS
symptoms may also occur with lower doses and can be more persistent and severe (Leon
et al., 2010).
Neuroleptic malignant syndrome (NMS) is a life-threatening neurological
disorder associated with antipsychotic medications. Symptoms of NMS are rigidity,
autonomic instability, altered level of consciousness, hyperthermia, and elevation of
creatine kinase and leukocytosis (Lieberman & Tasman, 2006). The onset can be sudden,
occurring usually in the early course of the medications. Understanding the potential risk
and recognizing these possibly life-threatening syndromes is critical to safely prescribing
antipsychotic medications to this older population with schizophrenia (Novick et al.,
2010).
General side effects of antipsychotic medications are varied and unique, as one
individual’s response to treatment may be quite different from another’s response to the
same medication. Some antipsychotics trend towards common side effects in a larger
portion of the population treated with the medication. Sedation is a common side effect of
specific medications and can be better tolerated with a bedtime dosing pattern. While
providing symptom relief of schizophrenia, practitioners need to be aware of the potential
of side effects to provide optimum care as safely as possible.
Table 1.3 reviews the major medications used in the treatment of schizophrenia
with information about metabolism, classification, dosing, excretion, peak level of drug
concentration (C-Max), half-life, protein binding, and special considerations for the older
adult population with schizophrenia.
12

Table 1.3
Medication Data
Drug Name

Available
Route/Dosing

HalfLife

Peak
Absorption &
Concentration Excretion
(Cmax)

Absorption Issues
and Special Notes

Serotonin-dopamine antagonist — SDA/SGA
Brand:
Zyprexa
(Generic is
Olanzapine)

Oral daily
dosing

21 to
54
hours

5 hours

85% GI / 40%
inactivated by
first pass
hepatic
metabolism.
Excreted 57%
renal, 30% by
GI. Protein
binding 93%.

No absorption
issues with food.
Luvox and
tagamet
increases serum
carbamazepine
and decreases
phenytoin levels.
Alcohol
increases
absorption by
25%.

Brand:
Relprevv
(Generic is
Olanzapine)

IM (Depot)
administer
every 2 to 4
weeks.

30
days

14-45 min

Absorption
rapid. (IM)

Post injection
delirium
sedation
syndrome
(PDSS) potential
— must be
observed for 3
hours after IM.

Brand:
Seroquel
(Generic is
Quetiapine)

Oral
(regular
2 times a
day dosing)

7
hours

1-2 hours

Rapidly
absorbed from
GI/ Excretion
73% renal,
20% GI.
Protein binding
83%.

Marginal effect
with food.
Phenytoin
increased
clearance 5
times normal.
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Brand:
Seroquel XR

Oral
(delayed
release,
daily dosing
3-4 hrs.
prior to
sleep)

9-12
hrs.

6 hours

Rapidly
absorbed from
GI/ Excretion
73% renal,
20% GI.
Protein binding
83%.

Absorption
slowed with high
fat foods (2252%)

Brand:
Geodon
(Generic is
Ziprasidone)

Oral (2
times daily
dosing
recmd.)

5-10
hrs.

2-6 hours

Bioavailability
doubles when
taken with
food (300 cal)
-absorption
rapid.
Excretion 20%
renal, 66% GI.
Protein binding
< 99%

Interactions with
other drugs that
prolong QT
intervals.

Brand:
Invega
(Generic is
Paliperidone)

Oral (daily
dosing)

4-5
days

24 hours

Bioavailability
28%. 74%
protein
binding.
Limited
hepatic
metabolism.
Excretion 11%
GI, renal 80%.
Protein binding
74%

With or without
food. Reduce
dose in renal
impairment.
Avoid with other
drugs that
prolong QT.

Brand:
Invega
Sustenna
(Generic is
Paliperidone
palmitate)

Depo (every
4 weeks)

25-49
days

1 day

Bioavailability
28%. 74%
protein
binding.
Limited
hepatic
metabolism.
Excretion 11%
GI, renal 80%.

2 initial doses
required. #1- in
deltoid (28%
higher
absorption),
#2.5-7 days later
in muscle of
choice.

14

Brand:
Risperdal
(Generic is
Risperidone)

Oral (daily
dosing)

Up to
17
hours

1-3 hours

Bioavailability
70%
Excretion:
70% renal,
14% GI.
Protein binding
90%

May inhibit
active metabolite
when used with
strong SSRIs
and elevate
prolactin level.

Brand:
Risperdal
Consta

Depo - IM
(every 2
weeks)

3-6
days

3 weeks

Bioavailability
70%
Excretion:
70% renal,
14% GI.
Protein binding
90%

Requires 3 doses
to reach steady
state (6 weeks).
Supplement with
oral medication
until after 3rd
dose.

Brand:
Clozaril
(Generic is
Clozapine)

1 to 2 times
a day

12
hours

2 hours

Bioavailability Unaffected by
50-60%.
food
Excreted 30%
GI, 50% renal.
Protein binding
97%.

Brand:
Fanapt
(Generic is
Iloperidone)

Oral (2
times a day
dosing)

(1)
18-26
hrs.
(2)
31-37
hrs.

2 - 4 hours

Hepatic
metabolism
excretion.
Protein binding
- 95%.
Excreted via
renal -58-45%
and 20-22% GI
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1) CYP 2D6
extensive
metabolizers,
2) CYP 2D6
poor
metabolizers.
Dose adjustment
needed. No
interaction with
food.

Brand:
Latuda
(Generic is
Lurasidone)

Oral (daily
dosing)

18
hours

1-3 hours

Renal and GI
excretion.
Protein binding
– 99%

Should be taken
with food (350
cal). Without
food absorption
impaired.
Grapefruit
products should
be avoided.

Brand:
Abilify
(Generic is
Aripiprazole)

Oral (daily
dosing)

75
hours

3-5 hours

Readily
absorbed.
Excretion 25%
renal, 55% GI.
Protein binding
<99%. Steady
state achieved
in 14 days.

Absorption
unaffected by
food. 99%
protein bound.
Clearance
reduced in
elderly.
Modulates
dopamine rather
than blocks.
Parent
compound is the
aripiprazole,
major
metabolite,
dehydroaripiprazole may
take longer ½
life (94 hrs.)

Brand:
Abilify
Maintena
(Generic is
Aripiprazole)

Depo- IM

29.9
days

5-7 days

Hepatic
excretion.
Steady state
achieved after
4 injections.
29% protein
bound.

Not tested or
recommended in
65 years or
older.
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Brand:
Saphris
(Generic is
Asenapine)

Sublingual
(2 times a
day)

24
hours

1 hour

Protein binding
95%.
Bioavailability
35%.
Extensive
hepatic
metabolism.
Excretion40% GI, renal
50%.

Drug Name

Available
Route/Dosing

HalfLife

Peak
Absorption &
Concentration Excretion
(Cmax)

No food or
liquid for 10
min. Caution
with Luvox.

Absorption Issues
and Special Notes

Dopamine Receptor Antagonist- DRA/FGA
Brand:
Haldol
(Generic is
Haloperidol)

Oral

10 to
37
hours

20 minutes
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Protein bound
90%
Bioavailability
60-70% 3340% renal
excretion, 15%
GI. High
potency

Well absorbed
from GI tract.
Smoking, coffee,
antacids and
food interfere.
Clearance
inhibited by
SSRIs, TCAs,
cimetidine, betablockers,
isoniazid,
methylphenidate,
erythromycin,
triazolobenzodiazepines,
ciprofloxacin,
and
ketoconazole.

Brand:
Haldol
Decanoate

Depot, IM

3 wks

2-6 hours

Peak
Smoking, coffee,
concentration 6 antacids and
days
food interfere
with absorption.
Clearance
inhibited by
SSRIs, TCAs,
cimetidine, betablockers,
isoniazid,
methylphenidate,
erythromycin,
triazolobenzodiazepines,
ciprofloxacin,
and
ketoconazole.

Brand:
Trilafon
(Generic is
Perphernazine)

Oral (2-4
times a day
dosing)

9-12
hrs.

1-3 hours

Bioavailability
20%.
Metabolism in
liver, GI tract.
Protein binding
90%. Medium
potency.

2-3 weeks for
desired results.
Lithium
formulation may
decrease serum
concentration of
antipsychotic.

Brand:
Oral (2-4
Thorazine
times a day
(Generic is
dosing)
Chlorpromazine
hydrochloride)

6
hours

2.8 hours

Bioavailability
32%. Protein
binding 9099%. Low
potency.

May cause
gynecomastia,
hyper- or hypo
glycemia.

Brand:
Prolixin
(Generic is
Fluphenazine)

33
hours

1-4 hours

Bioavailability
2.7%.
Metabolized via
hepatic system.
Protein binding
90%. High
potency.

Report CNS
effects (blurred
vision, altered
gait, excess
sedation urinary
retention)

(1-2 times
daily
dosing)
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Brand:
Prolixin
Decanoate

Depo, IM
(every 2-4
weeks)

Brand:
1-2 times a
Stelazine
day dosing
(Generic is
Trifluoperazine)

6.89.6
days

48-96
hours

Bioavailability
IM response
2.7%.
may last up to 6
Metabolized
weeks.
via hepatic
system. Protein
binding 90%.
High Potency.

24
hours

2-4 hours

Bioavailability
readily
available.
Metabolism
via hepatic.
Protein binding
>90%.
Medium
Potency.

Lower dose with
more gradual
increase for
elderly.

Note. Adapted from Physicians’ Desk Reference (67th ed.) by E. Strompf, 2012.
Copyright 2013 by PDR Network.
Definitions for Table 1.3
Atypical antipsychotic medications: synonymous with second-generation
antipsychotic medications (SGA).
Bioavailability: The fraction of the total amount of administered medication that
can be recovered from the bloodstream for use by the target tissue.
Half-life: The amount of time it takes for metabolism and excretion to reduce the
particular plasma concentration by 50%.
First-pass metabolism: The initial metabolism of orally administered medications
within the portal circulation of the liver referring to the fraction of absorbed drug
reaching the systemic circulation unmetabolized.

19

Metabolism: The liver being the principle site of drug metabolism, with feces, bile
and urine being the major routes of excretion. Antipsychotic drugs are also excreted in
saliva, sweat, tears and breast milk.
Protein binding: Percentage of drug bound to a protein molecule (albumin,
lipoprotein, glycoprotein, and globulins). Unbound portion of drug is readily metabolized
and or excreted whereas bound portion has higher half-life and slower release.
Potency: The amount of drug required for the drugs’ specific effect to occur.
Peak concentration (C-max): The maximum concentration a drug achieves prior
to a second dosing and a point to which short-term side effects are more likely to occur.
Neuroleptic medication: Synonymous with antipsychotic medication both typical
and atypical factors.
Typical Antipsychotic medications: Synonymous with first generation
antipsychotic medications (FGA)

In Table 1.3, the drug classes are grouped according to drug classes, listed as the effect
the medication has on the dopamine receptors in the brain. Further examination of
antipsychotic medications will continue in Chapter 2, as the effects of antipsychotic
medications by body systems will be examined in detail. Before moving on, it is
essential to take into consideration the many confounding factors of pharmacology.
Confounding Factors of Pharmacology
Medical comorbidities, physiologic changes of aging, polypharmacy, and alcohol
abuse, are common in the elderly patient. These concerns place older individuals with
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schizophrenia at elevated risk for adverse drug reactions from medication prescribed to
control symptoms. With the complexity of multiple issues co-occurring, the problems
increase for safe prescribing. Awareness of these issues is essential.
Medical Comorbidities
Long-term use of atypical antipsychotic medication is associated with a cluster of
related risk factors. Coronary heart disease had a significant increase over a 10 year span
of study for middle age and older adult schizophrenia patients (Jin et al., 2011).
Metabolic syndrome (MetS), which, when co-occurring with other disorders, increases an
individual’s risk of developing cardiovascular disease and insulin resistance leading to
various diabetic states and cardiovascular disease in adults was also a concern (Kisely,
Cox, Campbell, Cooke, & Gardner, 2009). Patients with schizophrenia had a higher
incidence of diabetes for the youngest adult age group when compared to the general
population (Hsu, Chien, Lin, Chou, & Chou, 2011). In a meta-analysis representing 48
studies of adults, clozapine and olanzapine had the highest risk of producing metabolic
issues including weight gain, altered glucose metabolism, and elevated triglycerides
within the class of atypical antipsychotics (Rummel-Kluge et al., 2010). The general
features of metabolic syndrome include elevated blood pressure, atherogenic
dyslipidemia, insulin resistance, and abnormal body fat distribution (Alberti, Zimmet, &
Shaw, 2006).
Other factors contributing to MetS include physical inactivity, aging,
proinflammatory state, hormonal dysregulation, and genetic predisposition (Alberti et al.,
2006). A high fat carbohydrate rich diet often associated with limited income also
increases the risk for MetS. Hyperlipidemia, obesity, and nicotine abuse contribute to
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medical comorbid health issues as well by further compounding the problems with
respiratory, musculoskeletal, and peripheral vascular issues.
Physiological Changes of Aging
Patients with schizophrenia often have metabolic issues that cause aging changes
to occur earlier than in the population without schizophrenia. Premature intracellular
deterioration in the older adult with schizophrenia precedes many metabolic health issues
(Jeste, Wolkowitz, & Palmer, 2011). The origin of this premature aging remains
debatable. There are several theories that try to explain this event. The first theory
outlines a course of declining health secondary to the cumulative systemic effects of
psychotropic medication. A second theory examines the contributing effect of the
inflammatory response with oxidative stress as a focal point. This response increases Creactive protein, cortisol, insulin, and suppresses certain anabolic hormones. Individuals
with schizophrenia were found to have increased T-cell activity (pro-inflammatory
activation), which is upregulated in acute inflammatory process, metabolic, and
cardiovascular disease (Suvisaari et al., 2011). These biochemical reactions create the
perfect environment for deterioration of the telomerase that is the protective cap at the
end of the DNA chain. Results of this loss link diabetes, insulin resistance, higher
cardiovascular disease, obesity, hypertension, and dyslipidemia to schizophrenia (Epel,
2009).
Early aging problems in the elderly brain associated with schizophrenia also cause
unique and confusing neurocognitive changes. Decreasing gray matter volumes in the
frontal and parietal lobes occur in the aging brain with schizophrenia (Jeste et al., 2011).
This cognitive change decreases the older adults’ ability to live alone and work
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successfully within healthy boundaries of self-care. Recognition of key medical issues
may also be diminished by the cognitive deficits of schizophrenia (Karim, Overshott, &
Burns, 2005).
Two additional factors that can impair cognition are directly within the control of
the practitioners prescribing skill. Antipsychotic medication decreases the positive
symptoms of schizophrenia by blocking the dopamine (D2) receptors. But blocking too
many receptors (greater than 80%) not only increases the risk of EPS, but also raises the
risk of cognitive impairment (Sakurai et al., 2013). The total percentage blocked was
estimated by measuring plasma levels of the antipsychotic concentrations using a
pharmokinetic model developed for the study. Although this level of analysis is not
common practice, the impact of antipsychotic medications in amounts high enough to
cause these symptoms is important for practitioners to recognize. Prescribing
anticholinergic medications to the older patients to reduce the symptoms of EPS becomes
the second factor that can damage cognition. A study of 1,780 patients aged 70 years and
older found using drugs with anticholinergic properties associated with low cognitive
performance (Lechevallier-Michel, Molimard, Dartigues, Fabrigoule, & Fourrier-Reglat,
2004). Recognition and achieving the correct balance of receptor blocking would
minimize the side effects while relieving symptoms. Choosing the correct medication,
dose, and monitoring for physical and cognitive changes is important for this older
population.
Physiologic changes as a product of aging place the elderly patients with
schizophrenia at elevated risk for adverse drug reactions. Two major organs of excretion,
liver and kidney, deteriorate with aging. This atrophy results in pharmacodynamic
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changes that may alter the expected response of either organ to the effect of a medication
(Hutchison & O’Brien, 2007). This atrophy is further complicated when the patients’
renal and hepatic system is additionally challenged by disease that further confounds the
process. Uncontrolled diabetes and hypertension are known to damage the kidneys when
symptoms management over time has been poor. This may lead to dialysis with severe
drug and dietary restrictions. As noted previously, hepatic function becomes impaired by
the ravages of hepatitis and cirrhosis secondary to disease, alcohol or drug use, or poor
lifestyle choices (Bowie, Serper, Riggio, & Harvey, 2005).
Fluid balance and the ability of the aging body to absorb, process, and excrete
successfully the antipsychotic medications both require close supervision. Diabetes, heart
failure, or instances of dehydration can alter the excretion and concentration of
medications by impacting blood levels of medications (Kaufman, 2011). Liver
impairment or disease may affect the efficiency of the metabolism of the drug (Sadock,
Sadock, & Kaplan, 2011). These examples may result in failure of the medications to
manage psychotic symptoms as the quality of the organ function is impaired by the
atrophy or disease.
Polypharmacy
In addition to the antipsychotic medications used to treat their mental illness,
aging patients with schizophrenia are more likely to be prescribed statins, non-steroidal
anti-inflammatories, insulin, antibiotics, diuretics, and modulators of kidney filtration and
hypoglycemic agents. Estimates indicate that 60% of drug reactions in older patients
with schizophrenia are caused by the following medications: glucocorticoids,
hypoglycemics, nonsteriodal anti-inflammatories and antibiotics (Perry, 2011). As these
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multiple medications are absorbed into the body, the neural pathway in which the
medication activates becomes overloaded causing conflicting medication efficiency. It is
critical for practitioners to carefully assess the combined pharmacological profile of
medical and psychiatric medications and their interactions within the aging body.
Substance Abuse
The comorbidities associated with schizophrenia in the elderly population may
also be exacerbated by alcohol and/or drug use. Binge drinking and non-medical use of
prescription drugs rank high in the elderly population (Blazer & Wu, 2011). A decreased
percentage of water in the aging body means less alcohol is necessary to cause
intoxication (Flood & Buckwalter, 2009). Alcohol and other drug use in the elderly may
compound age-related declines in mental abilities. Memory lapses, changes in sleep
patterns, and sleep deprivation may be more common in those who use alcohol and other
drugs. Consequently, it is essential to identify substance abuse problems. However, it is
important to be aware that symptoms associated with substance abuse such as confusion,
forgetfulness, poor diet, neglect of personal appearance, and hoarding may be
misinterpreted as symptoms of schizophrenia (Flood & Buckwalter, 2009).
Substance use may also result in falls or other accidents, especially in individuals
with pre-existing impairment of vision, balance, or mobility. Prolonged use of alcohol in
particular can contribute to the development or exacerbation of conditions that alter the
successful metabolism of medications (e.g. cirrhosis and chronic pancreatitis) or
complicate the overall health of the aging patient in general (e.g. compromise immunity
and hepatitis) (Hipwell, Singh, & Clark, 2000). The use of alcohol in combination with
antipsychotic medications alters the desired therapeutic effect of the antipsychotics
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allowing break through psychosis to occur and an increased occurrence of side effects.
Research examining the effect of alcohol on neuropsychological functioning noted a
more severe decline in cognition (Mohamed, Bondi, Kasckow, Golshan, & Jeste, 2006).
Additionally, a higher level of depression and non-compliance with prescribed
medications were found in the substance abusing elderly population with schizophrenia
(Margolese, Malchy, Negrete, Tempier, & Gill, 2004).
The occurrence of medical comorbidities within the elderly population is an
expected part of the aging process, but the degree of understanding that practitioners
exercise in prescribing for these conditions can greatly alter the final desired outcome.
The monitoring of MetS symptoms and cardiovascular disorders, the awareness of all
medications within the aging body and of the potential for alcohol and substance abuse
are important factors in caring for this population. Knowledge of the effects these issues
have on older patients’ physical health will help provide the necessary identification to
increase positive healthcare outcomes.
Synergy Among Factors Influencing Medication Management
Maximizing all of the resources available to cope with health concerns in caring
for the older population with schizophrenia may be the best approach for practitioners.
Under-recognition and under-treatment of medical risk factors, the patients’ sedentary
lifestyle or poor diet, and the contribution of adverse metabolic side effects from
antipsychotic medications (weight gain, dyslipidemia, and hyperglycemia) can combine
to undermine this population’s health outcomes. By combining the behavioral, medical,
and psychiatric interventions available, presenting issues can be treated more efficiently
as a group rather than individually.
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Additionally, a synergistic use of medications for treatment of the older
population with schizophrenia would maximize the pharmacologic outcome with a
minimum of complications from overloading the brain circuitry with polypharmacy. For
instance, use of one medication for psychosis as well as sleep or prescribing medication
more energizing with less sedentary side effects for issues related to weight gain or
ahedonia utilizes a synergistic approach. Management of schizophrenia for the older
population requires a delicate balance of pharmacology skills and knowledge of the
patient to achieve the optimum potential possible.
Along with symptoms management of schizophrenia, there are many additional
factors to be considered that may enhance the outcome of treatment. Arranging more
frequent monitoring and offering targeted symptom management and behavioral
components of treatment influences outcomes. Blending medical and psychiatric visits
for an all-inclusive picture of the older adult with schizophrenia for continuity of care
would bring the most gain for the least output. For example, additional medication is
indicated at times for depression, anxiety, mood stability, or co-occurring psychiatric
condition. Practitioners must then choose the proper medication to provide symptom
control without causing further complications. Following up with the necessary
monitoring of clinical indices for physical as well as mental areas of concern is indicated
as part of the best practice care practitioners can provide.
Addressing the necessary monitoring and points of concern that may alter the
current path of treatment is part of synergistic assessment. This approach may draw from
a variety of sources inside and outside practice to provide best care options for older
patients with schizophrenia. The focus is the patient as a whole. Choosing what
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components to initiate in addressing several issues at one time can maximize the limited
resources in the ever-narrowing mental health arena.
Project Focus
This project involves a detailed analysis of the literature on medication
management of older adults with schizophrenia in the community setting. The objective
of this project is to increase practitioners’ understanding of medication management by
increasing the ability to provide comprehensive, quality-focused care for this special
population. The literature is analyzed and ranked according to the strength and quality of
the evidence by examining the relevant research in aggregate to determine the strength of
the evidence, using the hierarchal method proposed by Melnyk and Fineout-Overholt
(2005). The hierarchy contains seven levels with I being highest quality and VII lowest
quality. The levels are based on the ability of the design to protect against threats to
internal and external validity. An evidence table will show the available literature
analysis with the strongest data chosen as best practice recommendations.
Evidence-based question. Creating evidence-based practice inquiry begins with a
specific format. This format, labeled PICOT (patient population, intervention of interest,
comparison intervention or status and outcome, time), produces the best evidence and
most relevant information (Melnyk & Fineout-Overholt, 2005). The PICOT definitions
are seen in Table 1.4. The EBP question is “In community dwelling older adult with
schizophrenia, what is the best practice for antipsychotic medication management?”
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Table 1.4
PICOT Definitions
Population

Intervention

Comparison

Outcome

Time

Community
dwelling older
adults with
schizophrenia

Medication
management for
schizophrenia

Changes in
medication
management
because of drug
actions and side
effects, comorbidities,
physiological
changes due to
disease and age

Safe and
effective
medication
management

Current

Summary
The expanding population of elderly individuals with complex health problems
requires extensive comprehensive care. Understanding the ever changing mental health
system continues to provide challenges both providers and patients must navigate in order
to be successful. The lack of clinical guidelines to manage older adults with
schizophrenia will present unprecedented challenges for health care providers as this
population grows. The aging bodies’ many ongoing changes, co-occurring medical and
29

psychiatric issues, multiple medications and providers, side effects, and the potential of
substance abuse and non-compliance all cloud this navigation.
Selection of medications for the aging patient with schizophrenia requires careful
analysis of factors including the patient’s age, the duration of time the patient was been
treated with antipsychotic medication, and the individual patient’s health profile.
Determination of appropriate antipsychotic medication presents the practitioner with
myriad options. Patient exposure to decades of antipsychotic medications with
subsequent side effects warrants special practitioner attention. However, use of
medications within the older population, with aging body systems, requires extra scrutiny
and vigilance to provide safe effective care.
Therefore, it is important for providers to be equipped with the knowledge to
maximize patient outcomes. Compiling, evaluating, and ranking the scattered literature
relevant to the care of older adults with schizophrenia will provide clarity regarding the
best clinical medication management. In the following chapter, normal aging,
schizophrenia, and medication issues will be examined by body systems to provide a
context for the analysis of best-practice medication management for community dwelling
older adults with schizophrenia.
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Chapter 2 Physiological Analysis
Patients who are 65 years and older with schizophrenia provide practitioners with
multiple pharmacological challenges. Although the speed at which aging occurs within
the body is unique to each individual, aging ultimately results in a gradual slowing of the
systems that govern the pharmacokinetic profile of medications. Providers must consider
these changes when prescribing medications for aging adults. Coupled with the
complexity of antipsychotic medications, the task of prescribing for this population may
seem daunting. Pharmacological research focusing specifically on this population is
historically limited because of the complicated health issues and polypharmacy
presentations, as well as researchers’ ethical concerns over the manipulation of this more
fragile group (Howard, 2010; Perry, 2011). However, in preparation for the expansion of
the geriatric population over the next quarter century, pharmacology research involving
older adults is beginning to grow. Geriatric psychopharmacologists suggest the
relationship between the general medical and neurological conditions are closely
associated with aging. Careful focus on this connection may provide practitioners with
improved options when choosing medications using this knowledge (Meyers & Jeste,
2010). In this chapter, the core points of antipsychotic medication management for older
adults with schizophrenia are explored and common physiological issues important to
safe and effective prescribing practice are identified.
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The three major focal points impacting medication efficacies for older patients with
schizophrenia are physiological changes of normal aging (see Appendix A),
physiological changes in schizophrenia (see Table 2.1), and effects of antipsychotic
medications (see Table 2.2). The effects of these three points on the person as a whole
are discussed in the chapter’s narrative. Table 2.3 presents a comparative examination of
the interactions of normal aging, schizophrenia, and antipsychotic medications to explore
the commonalities that complicate medication management in this population. An
understanding of these issues will provide a basis for an exploration of the literature to
determine best practice to improve medication success and positively impact the quality
of care provided to this population.
Physiological Changes of Normal Aging by Body System
Pathophysiology researchers have found alterations in body function associated
with aging (see Appendix A). Certain physiological changes of aging specifically
influence the pharmacological treatment of older patients with schizophrenia.
An understanding of changes within the aging adult’s body is essential when considering
medical interventions for older patients with schizophrenia. First, aging leads to a gradual
diminished functional capacity of the organ systems. Cardiovascular, central nervous
system, and respiratory changes have the largest effect with reduction of blood flow, lack
of oxygen, and diminished stimulation to target organs. The net effect is reduced size,
decreased function, altered absorption, and regeneration issues leading to loss of efficient
cellular function of the organs.
The reduced cellular functions within the organs predispose the older patient to
reduced capacity or failure of the systems. These changes can result in myocardial
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infarctions (MI’s), coronary artery disease (CAD), hyperglycemia, and a higher potential
for fractures and falls. The bases of the lungs are less ventilated resulting in an
ineffective redistribution of blood to compensate. This results in falling oxygen levels
that become worse when the older adult is lying down, causing a risk for respiratory
failure. Surgery, bed rest, pulmonary edema, trauma, burns, or environmental events
exacerbate this hypoxic condition (McDaniel, 1992).
The altered physiology within the cellular functioning also impacts the
pharmokinetic values in the elderly. The distribution of medication is altered by the
change in the proportion of water and body fat present. Hydrophilic drugs may have a
smaller volume of distribution and concentrations could be higher than normal.
Lipophilic drugs could have an increased volume of distribution with a potentially
prolonged half-life (Shi & Klotz, 2011). Decreased serum albumin concentrations could
increase unbound plasma concentrations of highly protein-bound medications.
Decreased hepatic and renal function could also slow the clearance of metabolites and
drugs from the liver and kidneys to increase the drugs’ half-life (Cusack, 2004).
The addition of disease pathology overloads the system. Similarly, lifestyle
choices affect the baseline wellbeing of the individual. Polypharmacy issues may
complicate or overwhelm the entire system as medical and psychiatric medications are
prescribed. All of these factors would have a compounding negative effect on the overall
body of the aging patient. Alterations in physiological functioning associated with
schizophrenia have the potential to exacerbate changes individuals are already
experiencing as an expected result of the aging process. The physiological changes of
schizophrenia by body system are examined next.
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Table 2.1
Physiological Changes in Schizophrenia by Body System
Cardiovascular
• Increased risk of cardiovascular comorbidity, coronary artery disease, hypertension,
and altered lipid levels (Saha et al., 2007)
• Decreased estrogen levels associated with increased blood pressure and decreased
nitric oxide, increasing the risk of CV disorders and myocardial infarctions
(Hennekens et al., 2005)
• Peripheral endothelial tissue dysfunction increases morbidity (Israel et al., 2011)
Hematologic
• Increased presence of hyperlipidemia, hyperprolactinemia, and hyperglycemia
(Halbreich, Kinon, Gilmore, & Kahn, 2003)
• Impaired peripheral glucose metabolism with elevated glucose levels and
hemoglobin A1C (Steiner et al., 2012)
Respiratory
• Increased risk of chronic obstructive pulmonary disease (COPD), deteriorating lung
capacity, and respiratory problems (Leucht, Burkard, Henderson, Maj, & Sartorius,
2007)
• Small increase in lung cancer risk (Barak, Achiron, Mandel, Mirecki, &Aizenberg,
2005)
Gastrointestinal
• Increase in BMI and central adiposity (Steiner et al., 2012)
• Small decrease in risk for colorectal cancer (Barak et al., 2005)
Urinary
• Neurogenic bladder associated with Neuroleptic Malignant Syndrome (NMS)
(Caroff, Campbell, & Sullivan, 2007)
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Endocrine
• Increased risk of hypothyroidism (Carney, Jones, & Woolson, 2006)
• Increased risk of diabetes mellitus
• Increased occurrence of insulin resistance (Steiner et al., 2012)
Neurological
• Impaired cerebral glucose metabolism, especially the frontal lobe (Ward, Friedman,
& Schulz, 1996)
• Right lateral fusiform gyrus dysfunction causing impairment of facial recognition
and processing, contribute to social dysfunction (Quintana, Wong, Ortiz-Portillo,
Marder, & Mazziotta, 2003)
• Oligodendrocyte and myelin dysfunction associated with changes in synaptic
function and formation lead to progressive, mild cognitive impairment (Takahashi,
Sakurai, Davis, & Buxbaum, 2010)
• Decreased muscarinic and nicotinic receptors in caudate-putamen, hippocampus, and
selected regions of prefrontal cortex impair regulation of cognitive neurotransmitters
(Eyler, Kemp, Mirzakhanian, & Jeste, 2009)
• Loss of GABAenergic neurons and inhibitory interneurons is associated with
hippocampus hyperactivity, ventral hippocampus regulates dopamine neurons
responsivity (Grace, 2012)
• Decreased 5-HT2A receptors, increased striatal D2 receptors with increased
dopamine content or metabolism (Wong & Tol, 2003)
• Selective neuronal degeneration within the norepinephrine reward neural system
contributing to ahedonia (Karim et al., 2005)
• Loss of brain volume from reduced density of the axons, dendrites, and synapses
mediating brain's associative functions (Ward et al., 1996)
• Lateral and third ventricular enlargement and reduction in cortical volume (grey
matter) by up to 25% (Pantelis et al., 2005)
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• Grey Matter Volume (GMV) in superior temporal gyrus (STG) associated with
positive symptom severity, white matter impairment increases negative symptoms,
GMV reduced in temporal and mediofrontal cortex involved in positive symptoms
• Increased density of interstitial white matter neurons correlates to grey matter
interneuron deficit in the cortex (Rusch et al., 2007)
• Reduced symmetry in temporal, frontal, and occipital lobes
•Decreased amygdala, hippocampus, temporal and parahippicampal gyrus sizes cause
disturbance in limbic system and glutamate transmissions causing difficulty filtering
out incoming data, brain responds by releasing dopamine (Baiano et al., 2007)
• 30-45% thalamus volume reduction and sub nuclei neuronal loss (Ettinger et al.,
2001)
• Dysfunction of anterior cingulate basal ganglia thalamocortical circuit (positive
psychotic symptoms) and dorsolateral prefrontal circuit (negative symptoms)
•N-acetyl asparatate were lower in hippocampus and frontal lobes impairing neural
metabolism (Wong & Tol, 2003)
• Abnormal EEG with increased sensitivity to activation procedures, increased theta
and delta activity, decreased alpha activity, causing epileptiform activity, and more
left-side abnormalities (Nuechterlein & Dawson, 2002)
• Eye movement dysfunction with inability to follow moving target accurately,
disinhibition of saccadic eye movements (Alain, Hargrave, & Woods, 1998)
• Dysdiadochokinesia, astereognosis, primitive reflexes, and diminished dexterity
(Irani et al., 2011)
Immune
• Decreased T-cell interleukin (IL)-2 production, reduced number and responsiveness
of peripheral lymphocytes, abnormal cellular, humeral reactivity to neurons, and
presence of brain-directed (antibrain) antibodies
• Increased concentration of IL-1, IL-6, TGF-β, state markers and IL-12, IFN-λ, TNFα, and sIL-2R are trait markers of the disease
• Elevated C-reactive protein, oxidative stress markers (Steiner et al., 2012)
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• Increased apoptosis may account for tumor resistance with tumor suppression
indicating a decreased incidence of cancer (Barak et al., 2005)
• Hyperprolactinemia alters the modulation of mononuclear cells of immune-cell
function (Halbreich et al., 2003)
• Reduced length of telomeres causing cellular degeneration and premature cell death
(Jeste et al., 2011)
Musculoskeletal
• Increased prolactin levels causing hypogonadism increasing risk of osteoporosis
(Halbreich et al., 2003)
• Abnormal performance on cerebellar-dependent tasks with decreased complexity of
postural sway; abnormal changes in association with removal of visual input causing a
disturbance of gait (Kent et al., 2012)
• Decreased risk of rheumatoid arthritis (Leucht et al., 2007)
Reproductive: Female
• Small increased breast cancer risk at younger age, and higher risk for postmenopausal women (Barak et al., 2005)
• Increased prolactin levels cause decrease in estrogen levels with potential decreased
libido or anorgasmia (Halbreich et al., 2003)
Reproductive: Male
• Increased prolactin levels cause decreased estrogen levels and libido, ED, delayed
orgasm, anorgasmia, retrograde or painful orgasms (Halbreich et al., 2003)
• Small to medium decrease in prostate cancer (Barak et al., 2005)
Sensory: Vision & Olfactory
• Elevated blink rate (hyperdopaninergic) (Ross et al., 1999)
• Abnormalities in olfactory receptor neurons with decreased ability to detect and
identify odors (Turetsky et al., 2003)

37

Skin & Hair
• Small to medium decrease of malignant melanoma (Barak et al., 2005)

Physiological Changes in Schizophrenia by Body System
Studies have shown schizophrenia to be a life-altering disease. Compared to the
general population, individuals with schizophrenia experienced accelerated physical
aging with increased and premature medical comorbidities and mortality (Jeste et al.,
2011). Researchers have identified several common physiological changes inherent in
patients with schizophrenia. In younger patients with schizophrenia, a high proportion of
deaths are caused by suicide and accidents. Yet a substantial remaining proportion of
mortalities is due to physical illness (Brown, 1997). These illnesses may be influenced
by physiological changes associated with schizophrenia (see Table 2.1).
The main changes that occur within the body systems with the presence of
schizophrenia begin in the brain. Many of these changes bring about the positive and
negative symptoms of schizophrenia by affecting dopamine levels within the cortex.
Other changes affect the transmission of the neurochemicals within the brain, causing
alterations in cognition, the capacity to feel pleasure, and the ability to identify people,
objects, and events. Throughout the cardiovascular system there are increased risks of
heart disease, hypertension, and dyslipidemia with premature cellular death and lessened
immune responses to protect the vascular system from damage. Hyperglycemia and
insulin resistance occur at a higher level in this population, which leads to a higher
percentage of diabetics.
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The etiology of the physiological changes associated with schizophrenia is
unclear. Questions remain regarding whether individuals with schizophrenia develop
health issues contributing to reduced life expectancy and comorbid health issues, or
whether there are associated factors. These would include unhealthy lifestyle choices,
antipsychotic medications, or disease-inherent derangements predisposing them to these
problems. With the knowledge of aging and the effects of schizophrenia on the body
systems of the older individuals, an understanding emerges that provides insight for
practitioners to guide practice decisions. Table 2.2 examines medication commonly
prescribed for the treatment of schizophrenia and the many ways the presence of this
medication alters the functioning of body systems. This additional layer will complement
the total knowledge compiled and provide a basis for targeted analysis of problem areas
important for best practice care.
Effects of Antipsychotic Medications
In considering the prescribing practices for older patients with schizophrenia, it is
important to be aware of medication side effects, actions, and class warnings. The
information given by the FDA helps providers monitor potential side effects, offer
cautions for harmful drug/drug interactions, and guides precautionary details necessary
for safe prescribing practice. This section provides a table illustrating these factors and a
narrative overview of the most important findings. The two classes of antipsychotic
medications are examined through the effects, both positive and negative, on each body
system. Special warnings governing the prescribing practices for specific drugs are noted
within the table.
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The FDA’s Warnings
The Food and Drug Act of 1906 prompted the formation of the Food and Drug
Administration (FDA), the governing public health and consumer protection agency in
the USA. Under the approval and sanctions of this office, prescribers operate and utilize
FDA guidelines for safe use of medication. Drugs are subjected to rigorous testing with
proof of safety carefully examined.
The FDA issues warnings or alerts on the package inserts (PI) that accompany all
drugs to market and guide labeling and Physician Desk Reference (PDR) listings. The
strongest warning is the boxed warning (also called a bolded or black box warning). This
indicates that the drug carries a significant risk of serious or even life-threatening adverse
effects. Warning and precautions do not meet the definition of serious adverse reaction,
but are clinically significant events that may: (a) lead to potentially serious outcomes
unless dosage or regimen is adjusted, (b) require monitoring to prevent or manage the
potential of an adverse reaction, and (c) affect patient compliance when compliance has
potentially serious consequences (“Guidance for industry,” 2011). When the warning
extends to all the drugs in one class of medications, it is called a class warning. Class
warnings are typically issued when an across-the-board side effect is noted.
In 2003, the FDA issued a black box warning on all antipsychotic medications
written for the elderly with dementia because of sudden cardiac death risk (Leon et al.,
2010). Initially, the concern was an increase in cerebral vascular accidents including
strokes. The warning was amended to include increased risk of mortality related to
sudden cardiac death (Jouk et al., 2006). Further study revealed a risk of death in drug-
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treated patients between 1.6 and 1.7 times the risk of death in placebo-treated patients
(Strompf, 2012). Questions arise as to the best practice for treatment of the elderly patient
with schizophrenia who additionally suffer from dementia, as both disorders must be
addressed to provide quality care (Harris, Heaton, Schalz, Bailey, & Patterson, 1997).
Warnings regarding medications are areas continually revised and updated by the
FDA. The FDA sponsors contact sites via the web, consumer phone reporting, and
professional med watch e-lists to keep prescribers up to date on recalls, shortages, and
amendments to the PI (“MedWatch,” 2013). Safe medication prescription depends on
knowing the latest information and applying this information to the care of individual
patients.
It is also critical for prescribers to understand the effects of antipsychotic
medications on the body. The actions and side effects (see Table 2.2) from the first
generation antipsychotic, dopamine 2-receptor antagonist (D2RA) class, to the newer
generation of neuroleptic medications, serotonin dopamine antagonist (SDA) class, are
different in many ways with a few similarities. The degree the patient experiences these
side effects is also patient specific, but the trend tends to follow the side effect potential
in Table 2.2.
With the discovery of the first antipsychotic medication in the mid-twentieth
century, the potential for enhancing the lives for patients with schizophrenia opened up to
new possibilities. However, over time, adverse response to these new medications
became apparent.
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Table 2.2
Effects of Antipsychotic Medications by Body System
Cardiovascular
D2 receptor antagonist (D2RA)
Site/action specific
• Alpha-1 receptor
antagonist

Interactions
• Class warning (all)

Adverse reactions
• Decreased blood pressure,
orthostatic hypotension
• Fainting, falls

• Increased risk of
events in elderly
dementia patients
(Stahl, 2008)
• Elevated prolactin
level (Miller, 2004)

• Class warning (all)

• Disrupted enzyme
contractility in cardiac
cell, decreased cardiac
contractility, increased
circulating
catecholamines,
prolonged arterial and
ventricular conduction
refractory periods
(Stahl, 2008)

• Lower potency DRAs
more cardio toxic than high
potency drugs

• Cigarettes and alcohol
consumption may also
impact outcome

• Caution with other drugs
that may increase QT
interval to compound the
event (Thorazine, Haldol,
Mellaril drug specific)
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• Low estrogen, higher blood
pressure, and decreased nitric
oxide increase chance of
myocardial infarction
• Arrhythmias, postural
hypotension, cardiac arrest
• Torsades de Pointes (TdP)
(with IV use and or higher
doses)
• Thorazine specific: T-wave
blunting, depression of the ST
segment

Serotonin-dopamine antagonist (SDA)
Side effects

Interactions

Adverse reactions

• Weight gain, glucose
dysregulation, and lipid
abnormalities

• Class warning (all)

• Increased cardiovascular
events

• Alpha-1 receptor
antagonist

• Class warning (all)

• Fainting, falls

• Increased risk of
events in elderly
patients with dementia
(Strompf, 2012)

• Class warning (all)

• Death

• Increased visceral
obesity (Steiner et al.,
2012)

• Increased proinflammatory cytokines
and elevated C-reactive
protein (CRP) levels

• Increased complications

• Clozapine specific:
Increased risk of
myocarditis, pericardial
effusion, congestive
heart failure, and
cardiomyopathy,
(Strompf, 2012)

• 25% tachycardia noted

• Associated with higher risk
during first month of treatment

• Clozaril, Invega,
Saphris, Fanapt,
Geodon, Seroquel,
Saphris specific:
Prolonged QT interval

• Caution with other drugs
that may increase QT
interval to compound the
event

• Arrhythmias, cardiac arrest
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• Risperidone, Invega,
Latuda, Seroquel
specific: Elevated
prolactin (Strompf,
2012)

• Cigarettes and alcohol
consumption may also
impact outcome

• Increased risk of
cardiovascular disorders

Hematologic
D2 receptor antagonist (D2RA)
Site/action specific

Interactions

• Agranulocytosis,
thrombocytopenia or
nonthrombocytopenic
purpura, hemolytic
anemia, pancytopenia
can occur (rarely)

• Class warning (all)

Adverse reactions
• Mortality rate is 30%

• Leukopenia,
neutropenia, and
agranulocytopenia
(Strompf, 2012)

Serotonin-dopamine antagonist (SDA)
Site/action specific

Interactions

Adverse reactions

• Leukopenia,
neutropenia,and
agranulocytopenia

• Class warning (all)

• Compromised immune system

• Elevated fasting
triglycerides, insulin
resistance

• Class warning - Initial
symptoms of metabolic
syndrome

• Increased appetite and weight
gain (variable by drug)

44

• Clozaril specific:
Significant risk of
potentially lifethreatening
agranulocytosis

• Drop in white blood cells
(WBC) and absolute
neutrophil count (ANA)

• Seroquel, Zyprexa
specific:
Hyperlipidemia
(Strompf, 2012)

• Compromised immune system
and possible death

• Increased risk of
cardiovascular events

Respiratory
D2 receptor antagonist (D2RA)
Site/action specific

Interactions

Adverse reactions

• Blockage of
muscarinic cholinergic
receptors (Stahl, 2008)

• Decreased bronchial
secretions

• Mucous occluding small
airways in patients with asthma
or bronchitis

• Increased risk of
bronchial pneumonia
(Strompf, 2012)

• Sedation, decreased
secretions, hypoventilation,
dehydration, and
hemoconcentration
contribute

• Compromised respiratory
system

• Mellaril specific:
Central nervous system
depression (Strompf,
2012)

• Enhanced by use with
sedative/hypnotic

• Respiratory depression with
distress potential

Serotonin-dopamine antagonist (SDA)
Site/action specific
• Blockage of
muscarinic cholinergic
receptors (Stahl, 2008)

Interactions
• Decreased bronchial
secretions
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Adverse reactions
• Mucous occluding small
airways in patients with asthma
or bronchitis

Gastrointestinal
D2 receptor antagonist (D2RA)
Site/action specific
• Muscarinic
cholinergic receptor
blockade (less with
Haldol) (Stahl, 2008)

Interactions
• Decreased salivation

Adverse reactions
• Dry mouth, constipation,
dental caries, ulceration of
gums, and buccal mucosa

Serotonin-dopamine antagonist (SDA)
Site/action specific

Interactions

Adverse reactions

• Drug specific bias
(espy. Clozapine,
Zyprexa, Saphris,
Latuda, Seroquel):
Weight gain (Strompf,
2012)

• May be compounded by
other weight-causing drugs

• Weight gain - Frequently a
cause of discontinuation

• Muscarinic
cholinergic receptor
blockade (Stahl, 2008)

• May be compounded by
other drying medications

• Decreased salivation

• Esophageal
dysmotility

• Drug specific: Seroquel

• Blockage, N/V

• Invega specific:
gastric narrowing

• Blockage and stricture
potential when GI disease
present
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• Difficulty swallowing

• Risperidone specific:
Dysphagia (Strompf,
2012)

Urinary
D2 receptor antagonist (D2RA)
Site/action specific
• Muscarinic
cholinergic receptors
blockage

Interactions
• Difficulty urinating

Adverse reactions
• Bladder distention, urinary
retention

Serotonin-dopamine antagonist (SDA)
Site/action specific

Interactions

• Muscarinic
cholinergic receptors
block. (Stahl, 2008)

Adverse reactions
• Bladder distention, urinary
retention

Endocrine
Serotonin-dopamine antagonist (SDA)
Site/action specific
• Endocrine bioactivity
from excess visceral
adipose tissue
increasing systemic
inflammation (Buckley,
Miller, Singer, Arena,
& Stirewalt, 2005)

Interactions
• Synthesize and release
bioactive molecules:
Interleukin (IL)-1, Il-6,
Tumor Necrosis Factor
(TNF), increased
monocytes and CRP

Adverse reactions
• Reduced insulin resistance,
induce insulin resistance of the
insulin-sensitive glucose
transporter in the peripheral
tissue
• Elevated triglycerides (with or
without weight gain)
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• Postsynaptic M3
muscarinic cholinergic
receptor blockage (high
probability with
Olanzapine, Clozapine)
(Lipscombe et al.,
2011).

• Reduces insulin releaseBeta cell failure

• Hyperglycemia, diabetic
ketoacidosis (DKA) and
hyperosmolar syndrome (HHS)

• Hyperglycemia,
diabetes mellitus risk
increased (Okumura et
al., 2010)

• Class warning (all)

• Metabolic syndrome

Neurological
D2 receptor antagonist (D2RA)
Site/action specific

Interactions

Adverse reactions

• Blockade of the D2
receptors in the
mesolimbic dopamine
pathway, reducing the
hyperactivity of the
pathway

• Reduction of the positive
symptoms of schizophrenia

• Blockage of the D2
receptors in the
nigrostriatal DA
pathway

• Blockage by dopamine
• Increased risk of EPS and TD
may allow acetylcholine
High discontinuing rate due to
unacceptable side effects
levels to become
overactive. Class warning.
Receptors become sensitive
over time and upregulate

• D2 antagonist reduced • Prevents dopamine from
in the tuberinfundibular binding to D2 receptors
pathway
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• Elevated prolactin levels

• D2 receptor
antagonist in the
mesocortical pathway
to the dorsolateral
prefrontal cortex

• Reduced dopamine

• Cognitive and negative
symptoms

• D2 receptors blocked
in mesocortical DA
pathway to
ventromedial prefrontal
cortex (Stahl, 2008)

• Reduced dopamine

• Affective and negative
symptoms

• Neuronal brain
changes (Dean, 2006)

• Neurotoxicity, apoptosis,
DNA fragmentation,
deficits in DNA repair,
deficits in function of the
mitochondrial respiratory
chain, and changes in
levels of Neurotrophic
factors (NTF) (observed in
rodents)

• Unknown

• Histamine 1 receptor
antagonist.

• Drowsiness, increased
appetite, with high
discontinuing rate as a result

• Alpha 1 inserted

• Dizziness, drowsiness

• Block D2 receptors in
the mesocortical and
mesolimbic DA
pathway (Stahl, 2008)

• Causes or exacerbates
negative or cognitive symptoms

• Blockage of
muscarinic cholinergic
receptors (Strompf,
2012)

• Class warning (all)
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• Cognitive blunting,
drowsiness, memory
impairment, and confusion

• Lower seizure
threshold

• Class warning (all)
• Lower potency drugs are
higher epileptogenic

• Higher incidence of seizures if
pre-existing seizure disorder
present

• Neuroleptic
Malignant Syndrome
potential (Strompf,
2012)

• Class warning (all)

• Death possible without
treatment and rapid recognition
of symptoms

Serotonin-dopamine antagonist (SDA)
Site/action specific

Interactions

• 5HT2A antagonist
occupies 5HT2A
receptors on
mesolimbic dopamine
neuron causing
dopamine release.

• Cognitive, affective, and
negative symptoms are
reduced

• 5HT1A (inhibitory)
and 5HT2A
(excitatory) regulate the
dopamine release.
5HT2A antagonist
blocks serotonin
excitation of the
cortical pyramidal cells
decreasing glutamate
release, reducing the
hyperactive drive on
the mesolimbic
dopamine pathway
downstream

• Reduced hallucinations
and positive symptoms
• Reduced binding
(disinhibition) at D2
receptor also decreased
EPS

• Dopamine regulation
in the mesocortical

• Mediate affective,
cognitive, and negative
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Adverse reactions

pathway

symptoms

• D2 receptors blocked
in the nigrostriatal DA
pathway (Stahl, 2008).

• Class warning/Drug
specific: All in class except
Clozaril
• Receptors become
hypersensitive or
upregulate

• Initially hyperkinetic
movements, over time
developing into TD

• Increase in seizure
activity (Clozaril
highest).

• Class warning: Incidence
occurs with higher doses

• Higher incidence of seizures if
pre-existing seizure disorder

• Potential for cognitive
and motor impairment

• Class warning (all)

• Impaired use of motor
equipment

Immune
D2 receptor antagonist (D2RA)
Site/action specific

Interactions

Adverse reactions

• Elevated prolactin
level

• Class warning

• Decreased immune response

• Leukopenia,
neutropenia, and
agranulocytosis

• Class warning (all)

• Immunocompromised

Serotonin-dopamine antagonist (SDA)
Site/action specific
• Bioactive activity
from visceral adiposity
(Steiner et al., 2012)

Interactions
• Synthesize and release
bioactive molecules:
Interleukin (IL)-1, Il-6,
Tumor Necrosis Factor
(TNF), increased
monocytes and CRP
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Adverse reactions
• Pro-inflammatory response

• Leukopenia,
Neutropenia, and
Agranulocytosis
(Strompf, 2012

• Class warning (all)

• Immunocompromised

• Class Warning/Drug
specific: Invega, Risperdal,
Seroquel, and Latuda

• Decreased immune response

)
• Elevated prolactin
level (Halbreich et al.,
2003)

Musculoskeletal
D2 receptor antagonist (D2RA)
Site/action specific

Interactions

Adverse reactions

• Elevated prolactin
level (Meaney, 2004)

• Class warning (all):
hypogonadism

• Increased risk of osteoporosis

• Blockade of the
dopamine receptors in
the basal ganglia
(Strompf, 2012)

• Class warning/Drug
specific: All in class except
Clozaril

• Movement disorders:
Akathisia, TD, EPS, and
hyperkinesis

Serotonin-dopamine antagonist (SDA)
Site/action specific
• Blockade of the
dopamine receptors in
the basal ganglia
(Strompf, 2012)

Interactions
• Class warning/ Drug
specific- All in class but
Clozaril Incidence less than
D2RA
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Adverse reactions
• Movement disorders: TD

• Potential for akathisia

• Drug specific: Abilify,
Risperdal

• Restless legs with "inner
restlessness" causing inability
to sit

• Elevated prolactin
level (Strompf, 2012)

• Class warning/Drug
specific (Risperdal, Invega,
Seroquel, Latuda):
hypogonadism

• Increased risk of osteoporosis

Reproductive (Male)
D2 receptor antagonist (D2RA)
Site/action specific
• Elevated prolactin
level

Interactions

Adverse reactions

• Class warning: Disruption • Decreased libido and arousal,
of the hypothalmisun- or hypo-orgasmia,
pituitary-gonadal system
galactorrhea

• Priapism, painful orgasm

• α-1 adrenergic
antagonist activity
(Strompf, 2012)

Serotonin-dopamine antagonist (SDA)
Site/action specific

Interactions

Adverse reactions

• Elevated prolactin
level (Invega,
Risperdal, Seroquel,
and Latuda specific)

• Class warning: Disruption • Decreased libido and arousal,
of the hypothalmisun- or hypo-orgasmia, and
pituitary-gonadal system
galactorrhea

• Increased risk of
priapism

• Drug specific: Fanapt,
Seroquel, Risperdal, and
Invega
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• Requiring medical attention

• Sexual side effects

• Blockage of
muscarinic cholinergic
receptors (Strompf,
2012)

Reproductive (Female)
D2 receptor antagonist (D2RA)
Site/action specific
• Elevated prolactin
level

Interactions

Adverse reactions

• Class warning: Disruption • Disruption of the menstrual
of the hypothalmiscycle, anovulation,
pituitary-gonadal system
galactorrhea, low estrogen
level, increased risk of breast
cancer (post-menopausal, premenopausal), and decreased
libido

Serotonin-dopamine antagonist (SDA)
Site/action specific

Interactions

Adverse reactions

• Elevated prolactin
level (Invega,
Risperdal, Zyprexa, and
Latuda specific)

• Class warning:
Disruption of the
hypothalmis-pituitarygonadal system

• Decreased libido and arousal,
un- or hypo-orgasmia,
galactorrhea, low estrogen
levels, increased risk of breast
cancer (post-menopausal, premenopausal), and decreased
libido

• Increased risk of
priapism

• Drug specific: Fanapt,
Seroquel, Risperdal, and
Invega

• Requiring medical attention
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• Elevated prolactin
• Disruption of the
level (Invega,
hypothalmis-pituitaryRisperdal, Zyprexa, and gonadal system
Latuda specific)
(Strompf, 2012)

• Decreased libido and arousal,
un- or hypo-orgasmia,
galactorrhea, low estrogen
levels, increased risk of breast
cancer (post-menopausal, premenopausal), and decreased
libido

Sensory
D2 receptor antagonist (D2RA)
Site/action specific

Interactions

Adverse reactions
• Blurred vision

• Blocked muscarinic
cholinergic receptors
• Retinal pigmentation

• Drug specific: Most
associated with Mellaril

• Early symptoms are nocturnal
confusion related to night
vision, may progress to
blindness

• Closed angle
glaucoma, ocular
dystonia, and cataracts
(Strompf, 2012)

• Usually associated with
high dose and prolonged
use especially Thorazine
and Mellaril

• Blurred vision, loss of vision,
and blindness if untreated

• Dysregulation of the
bodies’ core
temperature. (Strompf,
2012)

• Class warning

• Caution in conditions that may
elevate core temperature (e.g.,
exercising strenuously,
exposure to extreme heat,
dehydration)

Serotonin-dopamine antagonist (SDA)
Site/action specific

Interactions

• Closed angle
glaucoma, ocular
dystonia

Adverse reactions
• Blurred vision, loss of vision,
and blindness if untreated
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• Dysregulation of the
bodies’ core
temperature. (Strompf,
2012)

• Class warning

• Increased chance of
cataracts (Strompf,
2012)

• Drug specific (Geodon,
Seroquel) with long time
treatment

• Caution in conditions that may
elevate core temperature (e.g.,
exercising strenuously,
exposure to extreme heat,
dehydration)

Skin
D2 receptor antagonist (D2RA)
Site/action specific

Interactions

Adverse reactions

• Photosensitivity,
allergic dermatitis

• Drug specific: Thorazine
has high correlation to skin
changes

• Severe sunburn appearance or
long-term blue-grey
discoloration of skin resolves
when medication discontinued

• Macularpapular,
urticarial, petechial,
and edematous
eruptions (Strompf,
2012)

• May resolve
spontaneously

Mood and Behavior
D2 receptor antagonist (D2RA)
Side Effects

Interactions

Adverse Reactions

• Increased risk of
suicide

• Class warning (all)

• Elevated prolactin
level

• Class warning causing
decreased estrogen

• Hostility, anxiety, and
depression

Serotonin-dopamine antagonist (SDA)
Site/action specific

Interactions
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Adverse reactions

• Increased risk of
suicide

• Class warning (all).
Special caution with
antidepressant use

• Drug specific: Invega,
Risperdal, Seroquel,
Latuda elevated
prolactin level
(Strompf, 2012)

• Class warning causing
decreased estrogen

• Hostility, anxiety, and
depression

Both classes of antipsychotic medications, D2RA and SDA, have a major impact
on the overall health of the patient with schizophrenia. As a class in general, the D2RA
historically had more issues with movement disorders, prolactin elevations, and cardiac
arrhythmias. The SDA have been associated with more metabolic issues including
weight gain, dyslipidemia, and insulin resistance. Over time, the SDA have had added
prolactin issues and movement disorders associated with use. It is paramount to see
knowledge of antipsychotic medications as an evolving process.
The FDA web site offers updates to each drug with letters and addenda listed with
changes to the PI by date. Frequent updates of prescriber knowledge are necessary to
keep up to date with the newest findings of the FDA. Seminars and web-casts are offered
to providers and most states require continuing hours of education for license renewal in
medication updates. Drug representatives of specific antipsychotic medication are
usually a good source of new information on their products as well. Changes occur on a
continuous basis and safe prescribing practice requires practitioner attention.
In reviewing the depth to which these medications affect the body systems, the
age-related changes in peripheral and central pharmacokinetics contribute to the variable
degree of drug sensitivity in older age patients. Age-related changes contribute to
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increased sensitivity to side effects along the treatment pathway. However, absorption
factors and plasma concentration of antipsychotic medication are subject to the
influencing factors of smoking and renal dysfunction as causative factors of altered
clearance levels of medication. Pharmacodynamic changes within the dopaminergic
system interfere with antipsychotic sensitivity, and dosing for this population may need
adjustments to compensate.
Knowledge of the data in this medication table and performing careful
assessments of the older patient with schizophrenia allows a safety net to develop. Once
in place, guidelines can be set and patients can be monitored for individualized changes.
With the use of medication, the patient has the chance of functioning free of the positive
symptoms of the disease. Awareness of negative symptoms and system involvement is
the cornerstone of best practice care.
Cross Correlation of Aging, Schizophrenia, and Antipsychotic Medications
Elderly patients with schizophrenia are susceptible to the compounding factors of
age, disease state, and the onboard effect of prescribed medications. Research examined
many of these factors, but stopped short, in many cases, of closely inspecting how these
factors may interact to create treatment challenges. Table 2.3 illustrates correlations
across the previous tables to identify key focal points for practitioners. Included in the
table are items that appear in two or more tables across one body system, indicating areas
that require particular attention or monitoring by providers because of their potential to
interact in ways that complicate patient treatment. Table 2.3 supports this paper’s
premise that the best practice focus is on medication management considering drug
actions, side effects, and comorbidities along with physiological changes associated with
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both aging and schizophrenia. Geriatric psychopharmacologists must explore all aspects
of the older patient with schizophrenia — physical, medical and psychiatric— to
determine best practices for medication management.
Five main areas of concern for practitioners treating this population require
greater attention: metabolic syndrome, immune system depression, increased risk of
respiratory disease, cognitive impairment, and cardiovascular disease.
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Table 2.3
Correlations Identified by Body System
Normal Aging

Schizophrenia

Antipsychotics

• Increased risk of
morbidity, MI, CAD

Cardiovascular
• Increased risk of
morbidity, MI, CAD

• Increased risk of
morbidity, MI, CAD

• Decreased diameter
of vessels
•Increased blood
pressure

• Increased blood
pressure

• Decreased blood to
brain, kidneys
•Increased blood pressure

Hematologic
• Increased risk of
hyperlipidemia

• Increased risk of
dyslipidemia

• Increased glucose,
A1C
• Increased
prolactinemia

• Increased glucose,
A1C
• Increased
prolactinemia

Respiratory
• Less sensitive to
• Decreased lung
hypoxemia, increased risk capacity and increased
of respiratory failure,
respiratory problems
nocturnal hypoxemia, and
decreased vital capacity

• Decreased saliva, taste

Gastrointestinal
• Increased BMI &
central adiposity
• Decreased saliva

• Increased dental
problems with loss of
teeth

• Increased risk
pneumonia
(hypoventilation,
dehydration, sedation)

• Weight gain
• Decreased saliva
• Increased dental
caries, ulcerated gums
and buccal mucosa
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• Decreased colonic
muscle tone and motor
function

• Constipation

Urinary
• Decreased bladder
capacity and residual
urine, with increased
nocturnal frequency
• Increased insulin
resistance

• Cognitive impairment
with anticholinergic
effects of meds

• Decreased energy
production, blood flow,
and glucose consumed
• Decrease in dopamine
and dopamine receptors

• Reduced brain size
density
• Reduced
antibody/antigen
response
• Reduced thymic
hormones

• Increased risk of
osteoporosis

• Dysuria, bladder
distention and retention

Endocrine
• Increased risk of DM

• Increased risk of DM,
DKA & hyperosmolar
syndrome (HHS)

Neurological
• Progressive mild
cognitive impairment,
impaired
neurotransmitters of
cognition

• Cognitive, affective
and negative
symptoms, cognitive
blunting

• Impaired glucose
metabolism—
especially in the frontal
lobe
• Increased dopamine
content or metabolism
• Limited dopamine
neurons that can be
activated
• Reduced brain
density
Immune
• Reduced immune
response

• Decreased dopamine
with D2RA & SDA
•Prevention of
dopamine from binding
to D2 receptors
• Reduced brain size

• Increased C-reactive
protein and O2 stress
markers
Musculoskeletal
• Increased risk of
osteoporosis
Reproductive
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• Reduced immune cell
response
• Increased proinflammatory response

• Increased risk of
osteoporosis

• Decreased libido

• Decreased libido

• Decreased libido

Metabolic Syndrome
Metabolic Syndrome (MetS) is a metabolic disturbance formed from a cluster of
problems including hypertension, insulin resistance, dyslipidemia, and obesity. If left
unchecked, MetS can increase a patient’s risk for cardiovascular disease and diabetes
(Alberti et al., 2006). For an older patient with schizophrenia these risks are compounded
when poor nutritional food choices and budget constraints contribute to unhealthy diets.
Immune System Depression
Aging impacts the antigen/antibody system and the body’s speed of response to
invading organisms. The age-influenced reduction in thymic activity, depression of
immune cell response, and humeral response are all influencing factors (Solana, Pawelec,
& Tarazona, 2006). Elevated levels of prolactin in the body have both direct and indirect
impact on various pathological states as indicated by the prevalence of osteoporosis,
depressed immune response, increased cardiac events, and decreased libido. Having a
depressed immune system slowing the body’s ability to mount an immune response can
also have detrimental effects.
Increased Risk of Respiratory Disease
Medical practitioners should be aware that this population is at greater risk of
respiratory disease and respiratory failure. This results from several factors.
Polysubstance use and difficulty sleeping may predispose the older patient to use more
sedating agents or anticholinergic agents at night. Anticholinergic drugs or antipsychotic
drugs also cause serious side effects such as cognitive impairment (Lieberman, 2004) and
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block the muscarinic cholinergic receptors in the brain. This dries the mucous membranes
and further depresses respirations. These factors would be particularly harmful if a
patient had a pre-existing condition such as asthma or COPD.
Cognitive Impairment
Aging, the history of schizophrenia, and the use of antipsychotic medications all
effect cognition. Impairment of cognition impacts quality of life and the patient’s ability
to live alone. Some antipsychotic medications exert more influence over the negative
symptoms of schizophrenia while other medications induce cognitive blunting. Studies
indicate chronically institutionalized patients have a greater than average cognitive
decline and conversion to dementia (Jeste et al., 2011). Practitioners should be aware
that efforts to help the patient maintain a community-based existence might counter
cognitive decline.
Cardiovascular Disease
Cardiovascular disease (CVD) and increased risk of MI are found in the older
population as well as the patients with schizophrenia. According to Hennekens,
Hennekens, Hollar, and Casey (2005), CVD was the explanation for excess mortality
among people with schizophrenia. Aging, antipsychotic medications, and disease all
have major influence on the condition of the heart and cardiovascular system. Lifestyle
factors also influence those predisposed towards CVD. Substance abuse, diets high in
fats and of low nutritional quality, and non-compliance with prescribed medications for
treating dyslipidemia and hyperglycemia can all impact cardiovascular health in this
patient population.
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Summary
The older patient with schizophrenia experiences challenges associated with the
cumulative effects of an aging body, the disorder and medication use. As the
demographic shift occurs along with the increasing concern about comorbidity, and
mortality associated with antipsychotic use, a need to understand and maintain wellness
becomes evident. To minimize drug exposure while balancing the positive and negative
symptoms with least side effects is a major goal. Keeping a careful eye on the aging
body, with all the alterations of the many years of living, becomes a complicated task.
Health problems pinpointed in this chapter’s tables were target specific for this
population based on age, schizophrenia, and exposure to antipsychotic medications.
Awareness of the major health problems identified in this population provides
insight for practitioners regarding areas needing attention. Issues related to metabolic
syndrome (MetS), immune system depression, increased risk of respiratory disease,
cognitive impairment, and cardiovascular disease will be examined in detail using
evidence-based tables for graded research in these areas to determine best practice
recommendations for optimum care.
Chapter 3 provides the results of a literature search of these areas as they apply to
the treatment of older adults with schizophrenia. The focus will be medication and
changes in medication management because of drug actions and side effects,
comorbidities, and physiological changes due to disease and age.
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Chapter 3 Search Process
With the number of older adults schizophrenia increasing, practitioners face a
very complex situation for the context of care and action and side effects of drugs. This
evidence-based project’s focus is safe and effective medication management for the aging
population with schizophrenia.
Methodology
An evidence review was completed to address the PICOT question, “In
community dwelling older adults with schizophrenia, what is the best practice for
antipsychotic medication management?” The following sections describe the
components of the evidence review approach including: (a) description of evidence
sources; (b) search terms; (c) inclusion/exclusion criteria, and (d) search process.
Description of Evidence Source
A total of eight sources was searched: Cochrane Database of Systematic Reviews
(CDSR), National Guideline Clearinghouse (NGC) through the Agency for Healthcare
Research and Quality (AHRQ), U.S. National Library of Medicine via National Institute
of Health, Public Medicine (PUBMED), Cumulative Index of Nursing and Allied Health
Literature (CINAHL), Joanna Briggs Institute, Dissertations & Thesis: Full Text
database, PsycARTICLES, PsycINFO, and MedlinePlus (OVID). The current analytical
framework began with identification of the systematic reviews on the topics in
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current research. The search was then narrowed to focus more specifically on the articles
examining the select topics.
The search began with CDSR because it offers systematic reviews including
medical and pharmacological data on many relevant healthcare issues (Melnyk &
Fineout-Overholt, 2005). A systemic review is a high-level overview of primary research
on a specific question that seeks to answer that question by identifying, selecting,
synthesizing, and appraising quality research evidence relevant to the question
(“Evidence-based,” 2013). The key characteristics of the Cochrane review are (a)
utilization of clearly stated objectives with pre-defined eligibility criteria for studies; (b)
methodology that is explicit and reproducible; (c) search criteria that attempts to identify
all eligible criteria; (d) findings assessed for validity including bias, and (e) synthesis and
systematic presentation of the characteristics and findings of the included studies
(Higgins & Green, 2011). Systematic reviews of randomized clinical trials (RCTs) are
considered Level I evidence and are found at the top of the hierarchy of evidence with the
most rigorous approach to the minimization of bias (Melnyk & Fine-Overholt, 2005).
Focusing on the current PICOT question, this exploration process began with a search for
a systematic review of RCTs in medication management for older populations with
schizophrenia.
The second database searched was NGC via AHRQ. This is an evidence-based
guideline clearinghouse for clinical practice with quality measures. The mission of the
AHRQ is to improve the quality, safety, efficiency, and effectiveness of health care for
all Americans (“Mission,” 2014). The agency is a division of the U.S. Department of
Health and Human Services. The NGC supports a clearinghouse for links to full
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guidelines on specific health subjects (“About,” n.d.). This database offered superior
evidence-based guidelines to provide quality outcomes for medication management for
the treatment of older patients with schizophrenia when searched utilizing the PICOT
criteria.
The third search was of PUBMED because of the large, electronic biomedical
bibliographical records this site offers. PUBMED comprises more than 22 million
citations for biological and medical literature for MedlinePlus, life science journals, and
online books (“PubMed help,” n.d.). The United States National Library of Medicine
(NLM) at the National Institutes of Health maintains the database with the latest
information from the world of public medicine (“Fact Sheet,” n.d.). The PICOT question
prompted search of this site for peer reviewed, scholarly journals providing a valid,
unbiased meta-analysis or research, giving insight to medication management for the
older schizophrenic population to provide best-practice clinical care.
The fourth database in the search process was CINAHL, a large database for
nursing and allied health information. Records include comprehensive research indexes
with documents dating back to 1937 including 1,637 peer-reviewed journals in the
CINAHL database (“Full text,” n.d.). Melnyk and Fineout-Overholt (2005) consider
CINAHL a renowned source of comprehensive healthcare and scientific data.
CINAHL’s focus is nursing and allied health including overviews of diseases and
conditions with outlines of the most effective options for treatment relevant to the older
patients with schizophrenia.
The fifth source searched was the Joanna Briggs Institute, Dissertations & Theses:
Full Text database. This is a non-profit, international research and development
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organization that collaborates with over 70 entities across the world to promote and
support the synthesis, transfer, and utilization of evidence to improve healthcare
throughout the world (“About us,” n.d.). The site was searched to locate research into
schizophrenia in older adults and related focal areas of concern related to medication
management.
The sixth and seventh sources of data searched were PsychINFO and
PsycARTICLES. These bibliographic databases index scholarly literature in behavioral
sciences and mental health with a psychiatric, neuroscience, and nursing focus (Melnyk
& Fineout-Overholt, 2005). The American Psychological Association supports both sites.
PsycINFO has more than 3.4 million records for peer-reviewed journals, books, and
dissertations (PsycINFO, n.d.). PsycARTICLES is a database of full text articles from 90
landmark journals in behavioral science as well as nursing and neuroscience. All are
peer-reviewed, top psychology and social science journals (“PsycARTICLES,” n.d.).
Both sites offered timely research on the older population with schizophrenia including
medication management, drug studies, and recommendations for clinical practice.
The eighth database searched was MedlinePlus using OVID search technology.
MedlinePlus is the National Institutes of Health web site, produced by the National
Library of Medicine, the world’s largest medical library (“About MedlinePlus,” 2013).
OVID offers journal articles in life sciences with a concentration on biomedicine.
Tailoring the OVID search criteria facilitated a focused search for schizophrenia in the
older population with six selected journals using the medical subject headings (MeSH)
(“Overview,” n.d.). The goal was to target any relevant articles that enhanced the
biological and medical knowledge base of the project.
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Search Terms
Key terms used in the search were schizophrenia, older adult, antipsychotic
medication, side effects, comorbidities, and community dwelling. These were important
because of their link to the PICOT question. Older adults with schizophrenia living in
their communities were the specific population of interest. Records were further grouped
by searching via intervention, specifically medication management for schizophrenia, as
identified in the PICOT. Changes in medication management because of drug actions
and side effects, comorbidities, and physiological changes dues to disease and age were
identified while reviewing the articles of interest. Additionally, metabolic syndrome,
cardiovascular disease, cognitive impairment, immune system depression, and increased
risk of respiratory disease as they related to medication management were added to
further narrow the focus. The outcome of this thorough search of the available research
provides practitioners with evidence-based recommendations for the safe and effective
medication management of this specific population of interest.
Inclusion/Exclusion Criteria
The inclusion/exclusion criteria (see Table 3.1) were based on the PICOT
question for the evidence-based project. The terms used in the search included
antipsychotic medications, pharmacotherapy, side effects, elderly, and physiological
complications. Physiological complications included metabolic syndrome, cardiovascular
disease, cognitive impairment, increased risk of respiratory diseases, and immune system
depression. Evidence that qualified for inclusion targeted these criteria for clinical
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Table 3.1
Inclusion/Exclusion Criteria
Inclusions

Exclusions

adult population 65 years +
elderly and older (aging)
male and female
chronic schizophrenia
peer review journals
scholarly journals
antipsychotic medications
side effects
pharmacotherapy
1999 to 2013 (except landmark)
comorbid disease occurrences
physiological implications
metabolic syndrome
cardiovascular disease
cognitive impairment
respiratory diseases
immune system depression

schizotypal
diagnostic interventions
non-English language
acute schizophrenia
ECT
children
adolescent
early adulthood
middle adulthood (considered)

practice. Inclusion focused on the older population (65 years and older). Individuals
with chronic schizophrenia were the target population as they had the most exposure over
time to the medications and accumulation of comorbidities. Acute schizophrenia was
therefore eliminated. Institutionalized patients were excluded, as the focus is on those
living within the community not in nursing homes. The search was limited to peerreviewed publications. A ten-year period of time was selected for the most up-to-date
information with exceptions made for landmark or classic data. An exclusion for
schizotypal was related to the disorder’s classification as a personality disorder that may
be treated with therapy or other means. Diagnostic interventions and electroconvulsive
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therapy (ECT) were also excluded, as those topics were not a focus of this project.
Finally, children, adolescent, and early adulthood were also barred from the search as the
focus was on the older population. However, records that directly addressed the PICOT
terms that provided quality data and interventions for recommendations using a middle
adulthood group were considered for inclusion. Although these studies were not
exclusively focused on the elderly population, the data could be extrapolated to draw
inferential conclusions potentially applicable to the target population.
Search Process Description
In identifying relevant research studies unrelated documents were eliminated
using a Boolean search strategy, which combines terms together in a logical, concise
manner using inclusion or exclusion. The initial search utilized the most expansive term
— schizophrenia —combined with PICOT terminology of older adult, community
dwelling, and medication management.
Once the initial search was completed, the inclusion/exclusion criteria were
utilized to focus the search for a more targeted list of record results. Each topic was
searched separately as a subheading with the main topics remaining schizophrenia, older
community dwelling, and antipsychotic medication management. The additional
comorbid disease occurrences were added to the database of search criteria. The
summary from evidence sources is summarized in Table 3.2.
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Table 3.2
Search Process Summary
Evidence

Search Terms

Results

Cochrane

Schizophrenia +
antipsychotic
medications + older
adult

47 records:
Records for this search
addressed multiple drug
studies that were
inconclusive, short term and
not robust for
recommendations. Subjects
were young adults, or subject
matter was excluded topics of
this project.

National Guideline
Clearinghouse
(NGC)
via Agency for
Healthcare Research
and Quality
(AHRQ)

Schizophrenia +
older adults +
antipsychotic
medication
management

20 records:
Records excluded:
occupational therapy,
substance abuse, depression,
hepatitis, autism, pathways to
care, health lifestyle for
young adults, and Veterans
guides.

0

PUBMED

Schizophrenia +
older adult +
antipsychotic
medication (Table
3.1 criteria applied)

334 records found:
Exclusions: drug
comparatives, poorly
designed research, pregnancy,
autism, glutamate studies,
genetics, animal studies,
editorial, depression, quality
of life, alcohol and drug
abuse, social rehabilitation,
suicide, first psychotic break,
global representation and
perspective.

7

+ Schizophrenia
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Number
Retained
2

CINAHL

Schizophrenia +
older adult +
antipsychotic
medication (Table
3.1 criteria applied)

Joanna Briggs
Institute

Schizophrenia +
older adult +
antipsychotic
medication (Table
3.1 criteria applied)
Schizophrenia +
older adult +
antipsychotic
medication (Table
3.1 criteria applied)
Schizophrenia +
older adult +
antipsychotic
medication (Table
3.1 criteria applied)

PsycARTICLES

PsycINFO

MedlinePlus
(OVID)
Specific journals
chosen: Acta
Psychiatrica
Scandinavica,
American Journal of
Nursing, British
Medical Journal,
Journal of Clinical
Psychopharmacology,
Journal of Nervous
and Mental Disease,
Schizophrenia
Bulletin

Schizophrenia +
older adult +
antipsychotic
medication (Table
3.1 criteria applied)
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618 records found:
Exclusions: depression, acute
psychosis, poorly designed
research, clinical attitudes,
animal studies, stigma,
substance abuse in younger
age, psychosocial and quality
of life issues, negative and
positive symptoms, religion,
editorials, nursing home
residents and financial aspects
of schizophrenia.
29 duplicate or repeat articles
11 records found:
Exclusions: hospitalization,
younger adult articles, clinic
attendance and alternative
therapies
65 records found:
Exclusions: counseling
technique (CBT, DBT),
religion, family therapy,
coping, school-based issues.
44 records:
Exclusions: social
rehabilitation, family therapy,
perceptions of illness,
concepts, cost comparisons,
coping.
213 records:
Exclusions: psychosocial and
quality of life issues,
editorials, poorly designed
studies, rapid switching of
drugs, alcohol and drug abuse
with treatment
recommendations, animal
studies, stigma, first psychotic
break, family counseling.
Duplicates of / or repeat
articles – 32.

1

0

0

0
6

Summary
A systematic method was utilized to identify and retrieve evidence relevant to
clinical practice to provide best practice care for medication management of community
dwelling older adults with schizophrenia. After applying the inclusion/exclusion criteria,
the process initially involved searching through the listing of articles one by one for the
specific information desired. The availability of the electronic databases, full text article
downloads, and the consolidation of multi-journal sites of OVID helped to focus the
search. The evidence search resulted in a total of 16 articles and records being retained.
The findings identified in the search will be discussed in Chapter Four.
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Chapter 4 Evidence Synthesis
Focusing on safe and effective medication management for the aging population
with schizophrenia, this project’s aim was to develop an evidence table drawing on
quality evidence and presenting conclusions for medication management. This chapter is
divided into four sections: Evidence Table Development, Evaluation of the Evidence,
Analysis of Findings and Recommendations for Practice.
Evidence Findings and Analysis
Evidence Table Development
The search for articles appropriate for the EBP question and PICOT question
identified 16 articles related to medication used with elderly patients with schizophrenia.
The articles were entered into an evidence table using the headings: brief citations, level,
aim, design/setting/sample, intervention, outcome, and limitations. Mean age of the
population was noted where possible as the target age of interest for this evidence-based
project was 65 years and older.
Evaluation of the Evidence
The articles were analyzed using the hierarchal method proposed by Melnyk and
Fineout-Overholt (2010). The hierarchy contains seven levels with I being highest quality
and VII lowest quality. The levels are based on the ability of the design to protect against
threats to internal and external validity.
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Table 4.1
Evidence Table
Design/sample/
setting/number

Aim

Outcome

Limitations

Level I
Marriott, Neil & Waddingham (2006)/ Cochrane Collaborative
To
estimate
the effects
of antipsychotic
medication
for
treatment
of SZ in
people
over 65.

Systematic
review/ Three
randomized
clinical trials
(RCT)
evaluating
antipsychotic
drugs for SZ in
older people
2003-2010/
N=252.

Little robust data available to
guide clinicians to most
appropriate drug to prescribe for
elderly. Clinicians must
weighing risks and benefits.
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Small sample size
in one study; short
duration of all 3
studies (6-8
weeks) limited
results; some data
did not define how
randomization
occurred; no data
collected on global
or social
functioning or
quality of life;
Western bias to
data noted in 2
studies.

Aim

Design/sample/
setting/number

Outcome

Limitations

Level II
Essali, A, Ali, G. (2013)/ Cochrane Collaborative
To assess the
effects of
antipsychotic
drugs for
elderly
people with
late onset
Schizophrenia (SZ).

Systematic
Treatment will be by providers
review/ 38
using good clinical judgment
and habit to guide prescribing.
studies
identified in the
original
Cochrane SZ
Group with no
study meeting
criteria
retained;
updated 1/2/13
with 88 studies
identified with
one meeting
inclusion
criteria, 48 are
awaiting further
classification.
that compared
antipsychotic
drugs for the 65
years +
diagnosed with
SZ.
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Limited data
because only one
study met
inclusion criteria
for the review to
date.

Aim

Design/sample/
setting/number

Outcome

Limitations

Level II
Harvey, Napolitano, Mao, & Gharabawi (2003)/CINAHL
To compare
effects of
Risperidone
and
Olanzapine
on
cognition in
elderly
patients
with SZ or
Schizo
Affective
(SZ AFF).

RCT / Double
blind,
randomized,
parallel 8-week
study. (Mean
age: 71 yrs.)
Random
assignment to 1
to 3 mg/day of
Risperidone or
5 to 20mg of
Olanzapine
/Recruited in
and out patients
/ Diagnosed
with Sz or SZ
AFF. /N=176.

Low doses of Risperidone and
Olanzapine improved cognitive
function in elderly patients with
SZ or SZ AFF. The
improvements occur in aspects
of cognitive function related to
functional outcome.
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Results may be
influenced by
patients’ prior
higher-dose First
generation
antipsychotics
(FGA), which may
affect the tested
second-generation
antipsychotics
(SGAs) ability to
enhance cognitive
function.
Educational levels
of recruited by
vary in
multinational
trials.

Aim

Outcome

Design/sample/
setting/number

Limitations

Level II
Maixnew, Mellow, & Tandon, (1999)/ PUBMED
To assess the
efficacy,
safety and
tolerability of
antipsychotics
in the elderly.

Literature review
of pharmacologic,
clinical and
regulatory issues
involving
antipsychotic use
in elderly
patients,
compares FGA
and SGA, and
make some
general
recommendations/
140 citations and
references from
1955 to 1999.

FGA: Chlorpromazine - modest
efficacy, side effects limit use.
Thioridazine- moderate efficacy,
side effects limit use, low EPS,
high sedation, anticholinergic.
Haloperidol- moderate efficacy,
moderate side effects limit use,
High EPS, low sedation.
Thiothixene- insufficient,
conflicting data. Fluphenazineinsufficient data
SGA: Clozapine - Moderate to
good efficacy, very low EPS,
significant side effects, Dose
low and slowly titrate 6.2512.5mg/day. RisperidoneModerate-good efficacy, greatest
symptom reduction at 2mg
(increased side effects). Begin
0.25– 0.5mg /day to 1-2 mg/day.
Olanzapine - Moderate efficacy,
more data needed. 5 to 10 mg
best dose. Quetiapine - Moderate
efficacy, more data needed. Low
EPS. Begin 25mg daily. Average
dose 100-150mg/day. Range 25800mg /day. Summary- SGA
preferred due to better
tolerability. Elderly dose at 25%
that of young adult. Go slow,
start low, ongoing monitoring.
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Study limited
by the
absence of
data after
1999.

Aim

Outcome

Design/sample/
setting/number

Limitations

Level II
Ritchie et al. (2006)/ OVID
To compare
the efficacy
and safety
of
Olanzapine
and
Risperidone
in the
treatment
of elderly
patients
with SZ.

Quantitative
comparative
design/Recruited
60 yrs. + of
outpatients in
Australia
between 1998
and 2001).
Patients
switched from
FGA to SGA.
FGA had
inadequate
symptom
management or
side effects
issues. Patients
monitored every
6 weeks with
battery of testing
to measure
efficacy and
safety. (Mean
age 69.5 yrs.)
/N=61.

Both drugs were well tolerated,
and their use was associated
with fewer symptoms of SZ and
less adverse effects. Olanzapine
had a higher score on quality of
life. Olanzapine (mean dose
12.4mg/day)/ Risperidone
(mean dose 1.97mg/day).
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Difficulty with
recruitment
limited the sample
size and
diminished power.

Aim

Design/sample/
setting/number

Outcome

Limitations

LEVEL II
Suzuki et al. (2011)/ PUBMED
To examine
management
of SZ in late
life with
antipsychotic
medications
and
evaluated
treatment
resistance.

Qualitative
review/23
studies included
(8 double blind,
15 prospective/)
65 yrs. +
population with
SZ/1980 thru
4/2011/ N=23.

None.
Dosing: (average) Olanzapine11.7mg/day. Risperidone- 2.43.7 mg/day, (both preferred for
treatment resistance). Clozapine
- 53.2 mg/day. Fluphenazinewas well-tolerated. Mixed
results on aripiprazole and
quetiapine. Threshold for extra
pyramidal symptoms (EPS)
lower in elderly. High
vulnerability for metabolic
issues due to smoking and
lifestyle issues. Excess
mortality due to cardiovascular,
respiratory as well as suicide.
Caution with Clozapine and
anticholinergic burden. Little
difference in efficacy exists
between FGA and SGA.
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Aim

Design/sample/
setting/number

Outcome

Limitations

LEVEL II
Tzimos et al. (2008)/ PUBMED
To evaluate
safety and
tolerability
of
Paliperidone
extended
release (ER)
tablets in
elderly with
SZ.

RCT/ Recruited
outpatients
sample were
screened to
meet criteria
(Mean age 70
yrs.)/Multicenter
international 6
week, double
blind
prospective
study, with
open label
extension to 30
weeks/N=114.

Treatment over 30 days was
generally well tolerated and
may improve severity of
symptoms of SZ. Elevated
prolactin level in one-half
patients. Paliperidone ER 312mg/day.
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This study was
primarily
designed to obtain
safety and
tolerability data in
an elderly
population for
special
populations’
guidelines and
was not powered
for statistical
significance. The
data was
consistent with
efficacy results for
similar study in
younger age group
and was
generalized by
this study utilizing
the flexible dosing
design for this
population.

Aim

Design/sample/
setting/number

Outcome

Limitations

LEVEL III
Ciudad, Montes, Olivares, & Gomez (2004)/ PUBMED
To
evaluate
the safety
and
tolerability
of
Olanzapine
in an open
comparison
in parallel
groups that
compared
other SGA
in
treatment
with
outpatients
in the
treatment
of elderly
patients
with SZ.

Observational
prospective,
pharmacoepidemiologic
naturalistic
study/ SZ
outpatients. ≥60
yrs. of age
(Mean age 65.8
±5.9 yrs.)/from
EFESO study
in Spain/
/N=135.

Olanzapine has a favorable
patient profile in treatmentemergent adverse in elderly, less
probability of resistance to
treatment, increase global
functioning and improved
clinical severity. Mean dose of
Olanzapine was 11.7mg/day.
The combined use of two or
more antipsychotic drugs to
maximize treatment response is
frequent in daily practice. Less
anticholinergic drugs were used
as an adjunctive medication.
Somnolence and weight gain
were the top two side effects
found exceeding 10%.
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Small size of the
control group, no
randomization,
post hoc sample
from parent study,
concomitant
medications may
have affected
outcomes.
Statistical
significance was
not achieved due
to small size of the
control group.

Aim

Design/sample/
setting/number

Outcome

Limitations

LEVEL III
Davidson et al. (2000)/ PUBMED
To assess
the effects
of
Risperidone
in elderly,
chronically
psychotic
patients for
12 months.

Quasiexperimental
/Multicenter,
open label of
elderly patients
(65yrs +),
median age: 72
yrs.,with SZ or
other psychotic
disorder (0.5mg
2 times a day,
beginning dose
titration, could
be increased to
1.5mg to 4 mg
2 times a day)
/N=180

Long-term treatment was found
to continue both positive and
negative symptom
improvement, decrease in the
severity of pre-existing
symptoms of EPS, improved
Cognitive Global Impression
(CGI), and a low incidence
tardive dyskinesia. Average
dose 3.7mg/day.
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Lack of
randomization
decreased the
power of the
results.

Design/sample/
setting/number

Aim

Outcome

Limitations

LEVEL III
Jaskiw, Thyrum, Fuller, Arvamitis, & Yeh (2004)/PUBMED
To assess the
pharmacokinetics
and tolerability
of quetiapine in
elderly patients
with selected
psychotic
disorder.

Quasiexperimental
/Patients
recruited from
multicenter in
four states age
> 65 yrs. of age
(Mean age 71.8
yrs.)./an open
label Diagnosis
of Sz, SZ AFF,
or Bipolar,
rising multiple
dose trial.
Increased
dosing in fixed
step-wise
progression
reaching max of
250mg, 3 times
on day 21.
Total days of
testing 27.
Investigators
could halt
progression for
2 days if
intolerant./
/N=12

Pharmacokinetics of
quetiapine were identified as
linear. Side effects included
postural hypotension,
tachycardia and dizziness.
No QT changes observed.
The effective dose should be
introduced at a lower dose
and titrated at a relatively
slower rate in patients >65
yrs. old.
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Trial limited by
the small
number of
patients, lack of
a control group,
the open label
design.

Aim

Design/sample/
setting/number

Outcome

Limitations

LEVEL VI
Barak & Aizenberg (2003)/ OVID
To assess the
effects of
Olanzapine
on lipid
abnormalities
in elderly
psychotic
patients.

Prospective
quantitative /
elderly
inpatients
(Mean age 71.7
± 8.2 yrs.), SZ
AFF or SZ
exposed to
Olanzapine
(mean dosage
12.9mg/day)/6
month
(minimum)
Mean duration
of treatment,
289 days, with
follow up /
Israel/N=21

No significant change from
baseline serum lipid levels was
found for triglycerides or
cholesterol. No weight gain
was recorded. The association
of olanzapine exposure and
lipid abnormalities may not
hold true for older patients.
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Small size may
have decreased
the power of the
results.

Aim

Design/sample/
setting/number

Outcome

Limitations

LEVEL VI
Barak, Shamir, & Weizman (2002)/OVID
To assess if
switching
from a
typical
antipsychotic
to
Risperidone
would be
beneficial
for elderly
SZ patients

Naturalistic
retrospective
study/ elderly
inpatients
(Mean age 72.7
yrs.), followed
for 18 months
with SZ or SZ
AFF in Israel.
Treated with
either
Risperidone or
FGA
(haloperidol,
chlorpromazine,
perphernazine,
or 4 other FGA
not used in the
US) /Low
doses of
Risperidone
were used
(mean 2.3mg)
/N=51

Patients in both groups had
improved Positive and Negative
Symptom Scale (PANSS)
scores. Risperidone - CGI
scores reached significance at
18 months of the test and
antiparkinsonian meds were
used less frequently. Fewer
side effects. Basal Metabolic
Index was higher, but did not
reach statistical significance.
Side effects causing
discontinuation-FGA - EPS (1)
-Needed more anticholinergics.
SGA- Lack of efficacy (2)
Needed more sedatives to sleep.
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Naturalistic
setting of the
study including
non-random
distribution, preselection of
patients and nonuniform treatment
conditions may
affect the
outcome. There
was no washout
period, high use
of concurrent
medications and
possible inclusion
of treatment
resistant patients.

Aim

Design/sample/
setting/number

Outcome

Limitations

LEVEL VI
Finkel et al. (2009)/ PUBMED
To examine
metabolic
side effects
of yearlong
treatment
with
Clozapine,
Risperidone,
Quetiapine
or
Olanzapine
in
comparison
to treatment
with
Haloperidol
or
Perphenazine
among
elderly
individuals
with SZ.

A retrospective
chart review/
clinical records
of psychiatric
inpatients with
chronic SZ,
(Mean
age:FGA74.5yrs.SGA73.8.yrs.)
/Duration of 12
months/ in
Israel /N=228

Elderly patients may be less
susceptible to the MetS side
effects associated with SGA
agents than younger patient’s
populations.
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Broad exclusion
criteria limited
generalization of
results.
Combinations of
drug classes were
not screened.
Questionable too
old for study
sample at 74 yrs.
old. Bias results.

Design/sample/
setting/number

Aim

Outcome

Limitations

LEVEL VII
Alexopoulos, Streim, Carpenter, & Docherty (2004)/ OVID
To examine
an expert
opinion
survey on
antipsychotic
use in older
patients with
psychiatric
disorders
(SZ,
delirium,
dementia,
psychosis
mood
disorder)

Literature review and
expert opinion with
guidelines for
recommendations/survey
sent to geriatric
psychiatrists, geriatric
internists/47 question
survey with 1411
options / N=48.

None.
Consensus reached in
78% with 92%
completion of survey. SZrecommendations:
Preferred Risperidone1.25-3.5mg/day or
Quetiapine-100 to
300mg/day or Olanzapine
-7.5 to 15mg/day or
Aripiprazole -15 to 30
mg. /day. If the patient
with SZ has responded
well to treatment, the
experts recommend
reducing to the lowest
effective dose and
continuing treatment
indefinitely. For cognitive
impairment- preferred
Risperidone. For diabetes,
prefer Quetiapine or
Aripiprazole.
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Aim

Design/sample/
setting/number

Outcome

Limitations

LEVEL VII
Kohen, Lester, & Lam (2010)/ OVID
To explore
Aripiprazole
treatments
for the
elderly:
efficacy and
safety.

Expert opinion/
/Neuropsychiatric
Disease and
Treatment/ SZ or
SZ Aff/ 62 to
85yrs. old/ N=10

7 of 10 responded, 4 with
positive symptoms, 3 with
positive and negative
symptoms. Less EPS and preexisting EPS decreased. With
less antiparkinsonian meds.
Less sedation, weight gain,
anticholinergic effects, and no
QT prolongation. Improved
CGI scales at discharge.
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None.

Aim

Design/sample/
setting/number

Outcome

Limitations

LEVEL VII
Rado & Janicak (2012)/ OVID
To examine the
pharmacological
and clinical
profile of new
SGA
antipsychotic,
Paliperidone,
Iloperidone
Asenapine,
Lurasidone for
older patients.

Case report /A
review of
current data of
new SGA
/Examines
current trials
involving these
new drugs/ 65
yr. + patients
with
schizophrenia

In younger adults:
Paliperidone - useful in
hepatic failure. Major Side
effects: Iloperidone hypotension, QT
prolongation, Asenapine–
orthostatic hypotension.
Somnolence, improve
cognition, Lurasidone hypotension, QT
prolongation, cognitive
improvement. Drugs in study
are less likely to have
metabolic or EKG changes.
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Limited data
available at this
time on these
new SGAs use in
this age group to
recommend in
this population.

Level I evidence is from a systematic review or meta-analysis of all relevant randomized
controlled trials (RCT) or evidence based clinical practice guidelines based on systematic
reviews of RCTs. Level II is evidence obtained from at least one well-designed RCT.
Level III is evidence from well-designed controlled trials without randomization, and
Level IV is evidence from well designed case-controlled and cohort studies. Level V is
evidence from systematic reviews of descriptive and qualitative studies; Level VI is
evidence from a single descriptive and qualitative studies; Level VII is evidence from the
opinions of authorities and/or reports of expert committees (Melnyk & Fineout-Overholt,
2005, p. 10). The articles were organized from highest to lowest level. The evidence
table (see Table 4.1) displays one Level I studies, six level II studies, three level III
studies, three level VI studies, and three level VII studies. No studies fell into the
categories of Level IV or V evidence.
Analysis of Findings
Level I studies. The one Level I study was a systematic review of medications
best suited for elderly patients with schizophrenia. Marriott, Neil, and Waddingham
(2006) reviewed three randomized controlled trials comparing thioridazine with
remoxipride, risperidone with olanzapine, and olanzapine with haloperidol. They
concluded that there was no robust data to support the preferential selection of any of the
antipsychotic medications examined. The Level I study clearly indicated that there is
little scientific evidence to guide the selection of antipsychotics, with the exception of
olanzapine and risperidone.
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Level II studies. Expanding on Marriott et al.’s (2006) systematic review,
Suzuki et al. (2011) reviewed 23 studies, including eight RCTs, in an effort to synthesize
evidence related to management of late-life schizophrenia using antipsychotic
medications. They noted that over half of the studies were limited by small sample sizes,
and there is little robust data available to support any medications with the exception of
olanzapine and risperidone (which was supported for use in non-treatment resistant latelife schizophrenia). Similarly, Essali and Ali (2013) identified 88 studies pertaining to use
of antipsychotics for elderly patients with late-onset schizophrenia. Only one RCT,
comparing the effects of risperidone and olanzapine, met inclusion criteria. The authors
concluded that there is no convincing evidence to support the use of any specific
antipsychotic drug with this population. Suzuki et al. (2011) remarked on the lack of
evidence related to treatment resistance, antipsychotic polypharmacy, and medication
augmentation for older patients with schizophrenia.
More broadly, Maixner, Mellow, and Tandon (1999) conducted an extensive
review of the existing literature concerning pharmacologic, clinical, and regulatory issues
related to the use of antipsychotic medications in elderly patients. They concluded that
second generation antipsychotics (SGA), in general, had a favorable side effect profile
compared to first generation antipsychotics (FGA) because of the lower association with
extrapyramidal symptoms (EPS), but noted the paucity of scientific data to document the
efficacy and safety of antipsychotic medications for older adults, despite the frequency of
their use. The authors reviewed literature dating from 1955 through 1999, which is a
limitation in that more recent literature is not included.
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Ritchie et al. (2006) examined the efficacy and safety of olanzapine and
risperidone utilizing a sample size of 61 elderly patients with schizophrenia. Criteria for
inclusion included having completed a previous crossover study in which patients
switched from FGA to a SGA, and having experienced imperfect symptom control or
troublesome side effects while prescribed the FGA. During the comparative six-month
study, patients in the olanzapine and risperidone groups were assessed every six weeks.
The following rating instruments were used for monitoring: the Brief Psychiatric Rating
Scale; The Scale for the Assessment of Negative Symptoms; the Montgomery Asberg
Depression Rating Scale; the Mini-Mental State Examination; the Abnormal Involuntary
Movement Scale; the Barnes Akathisia Rating Scale; the Simpson Angus Scale; World
Health Organization Quality of Life instrument-brief. The study was limited by the
difficulty with recruitment, as many of the potential participants were already on
risperidone or olanzapine, and clinicians were reluctant to change patients’ current
medications. This reduced the available participant pool to less than 80 patient subjects,
decreasing the statistical power of the study. Additionally, cost concerns prevented the
use of a double blind study design. Results indicated that both drugs were well tolerated
and effective in reducing symptoms of schizophrenia with few side effects as compared
to FGA. Participants on olanzapine scored higher on a quality of life measure than
participants on risperidone. Patients switched to risperidone or olanzapine from FGA
improvements cannot exclude that the change in class of drugs and a reduction in dose
over time were the causative factors of improvement. The authors also noted a lack of
high quality evidence regarding use of antipsychotic medication in elderly patients with
schizophrenia.
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Harvey, Napolitano, Mao, and Gharabawi (2003) also examined the effects of
risperidone and olanzapine on cognition in a RCT involving 176 elderly patients with
schizophrenia or schizoaffective disorder over an eight-week period. Participants on both
drugs showed significant improvement in cognitive functioning at low doses. This study
concluded with the recommendation of longer studies for future research.
Tzimos et al. (2008) conducted a six-week RCT that examined the safety and
tolerability of oral paliperidone extended release (ER) in 114 elderly patients with
schizophrenia. A screening phase consisting of up to a five-day washout period
proceeded the six-week double blind phase. To ensure patient safety during this study,
patients were hospitalized from the first day of the double blind phase for at least 14 days
for monitoring. The eligible patients were then randomized 2:1 to receive a flexibly
dosed paliperidone ER or placebo once daily. Starting dose was 6mg a day. Doses
adjustments were increased weekly by 3mg increments, but decreased dosing could be
made at any time. Safeties of adverse events were measured using The Medical
Dictionary for Regulatory Activities Terminology Version 8.1, IFMPA, and Geneva,
Switzerland. Movement disorders rating scales, Simpson Angus Scale, Barnes Akathisia
Rating Scale and Abnormal Involuntary Movement Scale were used throughout the
double blind and open label phases of the study. The efficacy of paliperidone was
measured with Positive and Negative Symptom Scale, Clinical Global Impressions Scale
Severity Score. Personal and Social Performance Scale, and Schizophrenia Quality of
Life Scale were used in examining the efficacy of paliperidone on the patients’
perception of function, mood, and life. Clinical laboratory collection to monitor
metabolic data and body parameters included routine tests, plus serum prolactin, C-
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peptide and insulin, vital signs, body measurement, body weight, and 12-lead EKG. Of
the 38 patients in the original placebo group, 26 (68%) completed the six-week double
blind phase trial, and 64 of 76 (84%) of the paliperidone patients completed the study.
The study further offered an optional 24-week open-label extension in which 88 patients
continued. Paliperidone ER treatment was found to be well tolerated and may improve
symptom severity in elderly patients with schizophrenia. Prolactin levels were elevated
in one-half of patients. No adverse events were reported of any cardiovascular or QT
prolongation. Two patients with glucose-related issues and three patients with significant
weight increase were reported as experiencing adverse events. The authors further noted
the scarcity of data for treatment of schizophrenia in the elderly population, commenting
that only a handful of published studies have assessed tolerability of an SGA longer than
three months in duration. At least two design flaws must be considered in interpreting
and generalizing the results of this study. Due to small sample size, the study may not
have had enough power to determine significant group differences, and the short time
frame (six weeks) may also not be enough time for differences to manifest themselves.
In summary, Level II criteria provided five FGA and six SGA for examination
within six studies. Level II studies favored SGA for the elderly population for positive
and negative symptom management as well as positive effects on cognitive, and quality
of life outcomes. Compared to the safety profile of FGA, these medications were less
likely to be associated with the occurrence of EPS. Risperidone and olanzapine were the
most frequently examined medications, which could be due to their longevity on the
market. Prolactin level elevation was observed in patients medicated with paliperidone.

96

A lack of high quality studies in the elderly patient population that meet level II criteria
especially any of long duration was notable.
Level III studies. Three Level III studies were identified. Each well-designed,
controlled trial examined a different SGA in elderly patients with a psychotic disorder.
Ciudad, Montes, Olivares, and Gomez (2004) compared the safety and tolerability of
olanzapine to other antipsychotics with 135 elderly outpatients over 60 years of age.
Participants were non-randomly assigned to two groups. One hundred and five patients
were assigned to the olanzapine group and 30 to the comparison group. Half of those in
the control group received risperidone, and the remaining fifteen received medication
defined as high potency or low potency FGA. Assessment times included baseline, three
month, and six-month assessments, as well as spontaneous assessments as deemed
necessary by the provider during the treatment. Assessments included screening for EPS
using the Udvalg for Kliniske Undersøgelser side effect rating scale, Clinical Global
Impressions –Severity and Global Assessment of Function scales to assess patients
clinical status and effectiveness of medications. The Awad scale assessed the patients’
attitude regarding medications. Quality of life was measured using the EuroQol that
assess health state in five dimensions: mobility, personal care, daily activities,
pain/discomfort and anxiety. No significant group differences were found which could
be related to the small size of the control group. Participants in the olanzapine group had
lower akathisia, tremor, hypertonia, and higher incidence in insomnia, malaise, diarrhea
as compared to the control group. However, 10% had somnolence and weight gain.
Additionally, there was a lower use of anticholinergic drugs in patients taking olanzapine.
Olanzapine was effective in reducing the severity of symptoms and increasing global
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function at the end of the six-month follow-up as compared to treatment with other
antipsychotic medications, as reflected by an increase in the Global Assessment of
Function scores and a decrease in the Clinical Global Impression-Severity scale (Ciudad,
Montes, Olivares, & Gomez, 2007).
Davidson et al. (2000) conducted a yearlong study of risperidone enrolling 180
elderly patients with schizophrenia or schizoaffective disorder. The trial focused on the
effects of long term use of risperidone in the older population as measured by changes in
the Positive and Negative Symptom Scale (PANSS), EPS assessment including the
Extrapyramidal Symptom Rating Scale, and Clinical Global Scales, which were assessed
at one, two, three, six, nine, and 12 months during the study. A historical comparison
group was utilized to improve the validity of the interpretation of the results. This
comparison group with similar demographics and diagnoses of chronic schizophrenia was
treated with FGA for one year (Davidson et al., 1995). Greater than 50% of the patients
had both positive and negative symptom improvement at the endpoint. Risperidone was
well tolerated with lower incidence of tardive dyskinesia compared to participants in the
1995 study group. A decrease in the severity of the pre-existing EPS was observed with
a concomitant decrease in the use of anticholinergic medications. Cognitive
improvements were also noted, but could not be clearly attributed to treatment with
risperidone. Other factors affecting cognitive outcomes may have been a reduction in use
of anticholinergic medications, or the discontinuation of the previous antipsychotic
medication that may have caused the decline of cognition.
Jaskiw, Thryum, Fuller, Arvanitis, and Yeh (2004) assessed in a 27-day study the
tolerability of quetiapine in 12 elderly patients: eight with schizophrenia, two with
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schizoaffective disorder, and two with bipolar disorder. A more rapid titration of the
medication was chosen for this study to allow a longer pharmacokinetic testing time at
the desired dose range. This resulted in higher incident of adverse reactions including
postural hypotension and dizziness with a 30-50% reduction in the drug’s clearance from
the body. Prolactin was unaffected. The authors found quetiapine had favorable efficacy
and adverse effects profile in the 65 years and older population, with doses up to 250mg
given three times a day. This study was limited by its small sample size, uneven
distribution of male (nine total) and female (three total) participants, and a rapid titration
of medication. Future recommendation for replicating this study would suggest a slower
titration as a means of minimizing the negative side effects found in this study.
Considering the reduction of overall hepatic and renal clearance in the elderly population
that occurs with aging, a slower titration would be prudent.
In summary, Level III articles noted each of the three drugs — risperidone,
olanzapine and quetiapine — were effective in reducing symptoms of psychosis in
elderly patients with schizophrenia or other chronic psychotic disorder. Side effects
included somnolence and weight gain with olanzapine, and postural hypotension or
dizziness with quetiapine. Researchers recommended that medications be initiated at low
doses and titrated slowly in order to minimize side effects, keeping in mind potential
interactions and effects of concurrent medications. Improvement of psychosis may also
improve cognitive and global functioning. Caution was offered to monitor
anticholinergic medication suggesting less use for a more positive cognitive outcome.
Level VI studies. Three single descriptive or qualitative studies met criteria for
Level VI. Barak, Shamir and Weizman (2002) questioned whether switching from a
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FGA to risperidone would be beneficial. Fifty-one elderly subjects, age 65 to 88 years,
were chosen for this study. Twenty-five patients were treated with a FGA, including
haloperidol, perphernazine, chlorpromazine and four other FGA not FDA approved for
use in the US, and 25 patients were switched to risperidone with both groups monitored
for 18 months. Both classes of medications improved Positive and Negative Symptom
Scale scores. The results indicated switching was effective and well tolerated. Patients
switched to risperidone experienced improved Cognitive Global Impression Scale scores
and a reduction in side effects from the FGA including hypersalivation, sedation, and
apathy. The authors noted the Basal Metabolic Index was higher in the risperidone
group, but the difference was not statistically significant with patients noted to return to
near baseline at the testing’s endpoint. The incidence of EPS was higher in the FGA
group, which resulted in a greater need for anticholinergic medications. The risperidone
group used more concomitant sleep aids. This was thought to be due to the less sedating
quality of the risperidone as compared to the FGA. Limitations that may have affected
outcomes included a naturalistic setting, pre-selection of patients, non-uniform treatment
conditions, non-random assignment, no medication wash out period, high use of
concurrent medications, and inclusion of treatment resistant patients (Barak, Shamir, &
Weizman, 2002).
Barak and Aizenberg (2003) studied 21 elderly patients with schizophrenia or
schizoaffective disorder to assess the effects of first time exposure of olanzapine on lipid
abnormalities. The mean duration of olanzapine treatment was 289 days (SD± 139 days.
At the end of this prospective study, no significant changes from baseline lipid levels or
weight gain were found. Finkel et al. (2009), in a one-year retrospective study examining
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the metabolic side effects of clozapine, risperidone, quetiapine, olanzapine compared to
perphernazine and haloperidol in 228 elderly patients with schizophrenia, similarly found
no significant differences with respect to triglycerides or cholesterol levels. Additionally,
in examining the metabolic effects of FGA and SGA, the elderly patients’ Basal
Metabolic Index, body weight, blood glucose, B12 and folic acid levels remained
unaffected. The SGA carry a class warning for weight gain, lipid abnormalities, and are
associated with inducing the metabolic syndrome. Elderly patients may be less
susceptible to the metabolic side effects associated with antipsychotic medications than
younger populations. The elderly population as a group has a higher rate of chronic
conditions including cardiovascular disease and diabetes. Finkel et al. (2009) suggested
the mean age of this study, 74 years, was too old to represent the elderly population with
schizophrenia whose average lifespan is typically 65 years. Both studies suggested
further trials with larger, younger samples.
In summary, Level VI evidence suggested the elderly population might be less
susceptible to the metabolic challenges of the SGA. These would include cholesterol,
triglycerides and weight gain. Both FGA and SGA are effective in reducing Positive and
Negative Symptoms Scale scores. More EPS occurs with use of the FGA requiring more
anticholinergic medications. Studies that are more extensive are needed to explore the
metabolic and lipid changes in the elderly patients prescribed antipsychotic medication.
Level VII studies. Evidence from the reports of expert committees and/or opinion
of authorities comprises Level VII, the last level of the rating system. Three reports
qualified for Level VII. Alexopoulos, Streim, Carpenter, and Docherty (2004) developed
a 47-question survey based on a literature review to assess expert opinion on
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antipsychotic use in elderly patients with schizophrenia, delirium, dementia, delusional
disorder, and psychotic mood disorder. Fifty-two American experts in geriatric psychiatry
and medicine responded to the survey. The responses were used to write guidelines for
use of antipsychotics in older patients. Experts treating elderly patients with a diagnosis
of schizophrenia preferred risperidone 1.23-3.5mg/day, quetiapine 100mg-300mg/day, or
aripiprazole 15mg -30mg/day. If the patient response was successful, the expert panel
recommended reducing the medication to the lowest effective dose and continuing
indefinitely. The experts preferred risperidone for use in their elderly patients with a
cognitive impairment when diagnosed with schizophrenia and quetiapine or aripiprazole
for prescribing for patients with co-occurring diabetes.
Kohen, Lester, and Lam (2010) published a clinical article focusing on the safety
and efficacy of aripiprazole to treat schizophrenia in patients over 60 years of age. The
authors reviewed clinical trials with aripiprazole and elderly patients with schizophrenia,
as well as clinical studies involving psychosis in Alzheimer’s and Parkinson’s disease,
agitation associated with schizophrenia and bipolar disorder and the use of aripiprazole in
the older population group. Few studies were found completed to date on this topic and
population. Only one study within the article addressed the target population. Ten
elderly patients, age 62 to 85 years of age, with schizophrenia or schizoaffective disorder
were treated with aripiprazole. Seven responded to the treatment noting improved
Positive and Negative Symptom Scale and Clinical Global Impression score, less EPS
from prior medications, and less anticholinergic medications required to treat side effects.
Less weight gain and sedation were also observed. Improvements were based on prior
use of FGA and other SGA medications and clinical observations of patients’ behavior
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and Clinical Global Impression Scale assigned retrospectively. Based on prior reports,
clinical reviews and clinical practice experience, the effective dose range utilized for
safety and tolerability was 2 - 15mg/day for the elderly population. The authors further
suggested 20 minutes of exercise a day to reduce metabolic syndrome or providing
healthy food choices if patients were unable to exercise.
Rado and Janicak (2012) examined case reports describing the use of the new
SGAs for treatment of schizophrenia in elderly patients. The authors’ goal was to
examine these SGA because of the adverse effects profile of the FGA and the potential
alternatives offered by the new SGA in the elderly population. The case reports were
obtained from an extensive internet search of MedlinePlus, references from relevant
articles and abstracts from professional meetings. This report offered no new evidence
beyond that already reported concerning the use of paliperidone (Tzimos et al., 2008).
The author found no studies examining the use of luradone or iloperidone in elderly
patients and reported one study involving asenapine (Dubovsky, Frobose, Phiri, Greef &
Panagides, 2012). Prior research involving non-elderly populations has indicated that
patients treated with iloperidone, paliperidone, asenapine, and lurasidone are less likely to
have metabolic alterations than older SGA. Prolonged QT intervals and orthostatic
hypotension are side effects observed with iloperidone, asenapine and paliperidone.
Paliperidone, like risperidone, increased prolactin levels. The authors suggested
paliperidone for patients with hepatic impairment because of the drugs predominant renal
excretion. Asenapine and lurasidone were noted to improve cognition as measured by
improved Clinical Global Impression scores. These drugs need to be adjusted for renal
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and/or hepatic impairments. All of the new SGA have minimal research in the elderly
population. Further studies with adequately designed and powered studies are needed.
In summary, The Level VII evidence added the dimension of the newest atypical
antipsychotic medications on the market. Although not supported by scientific evidence,
clinical experts noted that these newer medications may have fewer metabolic issues, and
relatively low risk of prolactin elevations and EPS, while being effective at reducing
psychotic symptoms. Lurasidone’s low risk for hypotension and QT prolongation with
the potential of cognitive improvement may make it a useful agent in older people.
Cautions regarding risks of cardiovascular side effects were drug specific. Further
research will be needed to validate the Level VII evidence.
Recommendations for Practice
Relatively few robust studies have been conducted involving antipsychotic
treatment in elderly patients with schizophrenia. Unfortunately, there has been little
accumulation of new knowledge since 1999, despite the introduction of several SGA with
unique side effect and risk profiles. The limited research has left providers with little
guidance as to how to proceed with psychopharmacologic treatment in this population.
Reduced incidences of EPS and TD in SGAs have supported SGA use over FGA in all
age groups. There is some very preliminary evidence to suggest that SGAs are effective
for treating symptoms of schizophrenia in older patients and may be better tolerated than
in younger patients, with a lower incidence of metabolic issues. Researchers and clinical
experts recommend relying on the clinicians’ assessment and clinical reasoning skills
until more evidence becomes available.
General Clinical Practice Recommendations
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In general, providers are advised to identify the target symptoms to be treated,
weigh the risks and benefits of all potentially appropriate medications, and use best
clinical judgment to choose a medication based on the individual patient’s needs and
psychological/physiological status. Adherence is critical to successful treatment and
positive outcomes, therefore patients and families should be included in the decisionmaking process to simplify the protocol and maximize compliance.
The following recommendations are drawn from individual studies and expert
opinion and may only be used as data in the clinical reasoning process.
Recommendation 1. Perform a thorough diagnostic evaluation to include review
of systems, physical assessment, and laboratory analysis of cardiac, hepatic, and renal
functions prior to prescribing medications (Maixner, Mellow, & Tandon, 1999).
Recommendation 2. Second-generation antipsychotics are preferred over FGA
when choosing the best antipsychotic drug for the elderly patient (Alexopolos, Streim,
Carpenter, & Docherty, 2004; Finkel et al., 2009).
Specific medication recommendations based on safety and efficacy include:
Risperidone is identified as the number one choice (based on safety and efficacy)
(Alexopoulos et al., 2004; Barak, Shamir & Weizmann, 2002; Davidson et al., 2000;
Finkel et al., 2009; Harvey, Napolitano, Mao, & Gharabawi, 2003; Maixnew et al., 1999;
Marriott, Neil, & Waddingham, 2006; Ritchie, et al., 2006; Suzuki et al., 2011)
Olanzapine is the second choice (based on safety and efficacy) (Alexopolos et al.,
2004; Barak & Aizenberg, 2003; Ciudad et al., 2004; Harvey et al., 2003; Maixnew et al.,
1999; Ritchie et al., 2006; Suzuki et al., 2011).
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Quetiapine is the third choice (based on safety and efficacy) (Alexopolos et al.
2004; Jaskiw, Thyrum, Fuller, Arvamitis and Yeh, 2004).
Aripiprazole is the fourth choice (based on safety and efficacy)
(Alexopolos et al., 2004; Kohen, Lester & Lam, 2010).
Recommendation 3. The dosing range suggestion is to start low (25% of young
adult dose) and to titrate slowly with careful monitoring of side effects (Maixner et al.,
1999).
Recommendation 4. Avoid the use of anticholinergic medications when possible
because of negative effects to cognition (Ciudad et al., 2004; Kohen et al., 2010; Suzuki
et al., 2010).
Recommendation 5. The recommended frequency of follow-up monitoring to
evaluate antipsychotic treatment protocol is based on patient status.
•

Upon initiation of antipsychotic: Every one to two weeks until symptomatically
stable for one month on the same dose of antipsychotic medication.

•

Early in treatment monitor tolerability and therapeutic benefit every two to three
months until the patient has been stable for six months on the same medication
and dose.

•

Routine follow-up every three to six months if patient is stable and there have
been no medication adjustments.

•

Monitor 10 days to four weeks following an antipsychotic dose change
(Alexopoulos et al., 2004).
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Recommendation 6. Allow two weeks to assess whether symptoms are
adequately controlled before changing the antipsychotic dose or type of antipsychotic
medication, as long as the patient is tolerating the medication (Alexopoulos et al., 2004).
Recommendation 7. Continue antipsychotic treatment indefinitely at lowest
effective dose necessary to control symptoms of schizophrenia (Alexopoulos et al.,
2004).
The findings of this project will be reviewed and discussed in Chapter Five.
Clinical implications of the evidence and recommendations for future research will also
be addressed.
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Chapter 5 Outcome and Implications
Patients dealing with mental illness encounter many lifetime hurdles within the
mental health system. One challenge is to find the appropriate medication to help
manage symptoms. Advances in psychopharmacology include the frequent introduction
of new drugs to treat schizophrenia. Unfortunately, the older population is not included
in any significant trials of these new drugs. This follows the historical pattern of minimal
representation of older patients with schizophrenia in high quality drug studies of second
generation antipsychotic (SGA) medication. Despite an exhaustive literature search, only
16 articles were found that met inclusion criteria for this project. The majority of these
studies examined the older drugs, especially the first few SGA medications on the market
in the United States, in comparison with each other or with first generation antipsychotic
(FGA) medications. The newer drugs were mentioned as promising, but no viable
studies to date have been conducted. These studies provided little new insight into best
practice for the use of antipsychotics to treat older adults with schizophrenia beyond the
already known prescribing practices for this population.
There are many possible reasons for this absence of data. Recruitment of a
sufficient number of elderly subjects to participate and follow up may be difficult. The
researchers may want to avoid the confounding effects of other medical conditions and
medications. Reluctance to involve this more delicate population may also be a concern.
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Unfortunately, RCTs are not the ideal nor preferred method to study medication
actions for this more sensitive population. The pharmacokinetic and pharmacodynamic
response to medications in the elderly population is unique and best monitored in a more
naturalistic setting over longer time spans. These conditions are not easily managed
within the pharmaceutical six or eight week trial protocols preferred in most drug studies.
There is limited access to this population as well, as community dwelling elderly people
with schizophrenia are dependent on community resources for transportation and
coordination of care, which results in missed medications, lab work, and appointments.
During the search process, more studies were available examining the use of
antipsychotic medications in the elderly with dementia. This trend may be attributed to
better accessibility of the elderly population with dementia for participation and
monitoring in research, as they are more likely to reside in assisted living facilities or
nursing homes. There is also a larger pool of patients in the dementia population versus
the elderly population with schizophrenia from which to draw the study group.
To provide context for the evaluation of evidence, this project examined the
complex intersection of normal aging processes, physiological changes associated with
schizophrenia, and the action of antipsychotic medications to provide an overview of the
factors providers must consider in order to safely prescribe antipsychotic medications for
older adults with schizophrenia. The expected cognitive and physiological changes
associated with aging combined with comorbid conditions and polypharmacy can further
complicate the symptom management by affecting the tolerance and efficacy of
antipsychotics in aging patients. Unfortunately, for the reasons noted above, although
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the older population with schizophrenia is increasing, it is likely that high-level evidence
to guide prescriptive practice will continue to be lacking.
Nevertheless, awareness of the considerations outlined in the project can help
providers evaluate the potential for newly marketed drugs to be incorporated safely into
patients’ treatment regimens. Further, the information presented emphasizes the
importance of ongoing monitoring to determine the need for medication adjustment as
individuals age and their care becomes more complex. Proactively identifying the risks
to health in this fragile patient population will help prevent exacerbation of comorbid
health problems or the occurrence of complications requiring more medications and
increasing the potential for hospitalizations. Better overall health will allow older
patients with schizophrenia to live independently in the community for a longer period of
time and attain a higher quality of life.
Healthcare System and Community Resources
Providers’ knowledge and skills become even more critical because of the barriers
within the healthcare system to providing efficient care to this older population with
chronic, severe mental illness. From 2005 to 2010, 14% of psychiatric hospital beds
nationwide were closed, with four states closing an estimated 50% of their inpatient
psychiatric beds and another 13 states closing 25% of their total inpatient psychiatric
beds (“New Treatment,” n.d.). More and more, patients must depend on community
mental health providers for their psychiatric care. Due to the increasing life expectancy
and the aging of the baby boomer generation, there will be a greater number of older
patients with mental health disorders, including schizophrenia. Once an elderly patient is
established within the system, complicated insurance protocols, prior authorizations, and
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regulatory restrictions on prescribing can make offering a medication for symptom
management for elderly patients a daunting task. The Affordable Care Act (ACA)
mandates parity for treatment of mental health and physical illness. Unfortunately, this
comes at a time of decreased mental health funding and fewer medical students choosing
to enter psychiatry as a career, resulting in a lack of qualified mental health professionals
in a time of peak need (Thomas, Ellis, Konrad, Holzer, & Morrissey, 2009). Psychiatric
mental health nurse practitioners (PMH-NP), as the only other mental health provider
with prescriptive authority, have the opportunity to fill some of these gaps and make a
powerful impact in the lives of older patients with schizophrenia for whom medication is
an integral part of symptom management.
The system does try to optimize health for elderly patients with schizophrenia
enabling them to follow through with acquiring necessary care. Medical expenses are an
ongoing issue. Medicare is available to this population, as are the insurance benefits of
Medicare A and B. Choice for Medicare D coverage for medication coverage is the
choice of the individual, which leaves many patients questioning which plan to choose.
Co-payments for the patients are widely variable. Medicaid is available in some limited
financial circumstances for additional coverage to help defray the monetary burden of
medical care. Some areas offer a base form of case management, but with funding cuts
for mental health services, these are limited. Accessing care can also be problematic.
Transportation services are offered in some areas to help individuals with special needs,
whether physical or psychological, but the trend has been to begin charging a fee for each
way or per mile, which is difficult for those patients on limited income to afford.
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Community mental health facilities are available as well but typically in larger cities and
communities.
Regrettably, the weaknesses within the system for elderly patients with
schizophrenia outweigh the strengths in meeting their needs for services and care.
Limited access to mental health care remains a problem due to a shortage of qualified
providers and overcrowding of the existing mental health clinics. Funding cutbacks in
mental health services have reduced case management to almost non-existent except for
the most severely impaired patients. The logistics for the patient to maneuver the mental
health system, obtain lab work as requested, and fill out forms for insurance coverage as
requested become overwhelming. This population is more likely to be unmarried and
without children, requiring more independent functioning within the community. With
less support to draw upon in stressful times, the elderly population with schizophrenia is
more likely to be in need of an inpatient respite. However, with fewer hospital beds
available and poor individual support systems, the options are limited.
Limitations of the Project
This project was limited by the paucity of available quality research that included
older adults with schizophrenia. Ultimately, it was disheartening to learn that there is not
a lot of high-level research data available on the 65-year and older population with
schizophrenia. The majority of information available was anecdotal, not empirical. Most
empirical studies were descriptive and had limitations that resulted in few findings to
guide practice. Recommendations were broad and focused primarily on use of clinical
judgment. In order for clinical judgment to be useful, clinicians must have a clear
understanding of the type of medications available and associated actions, risks, and side
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effects. Further, the clinician needs a strong awareness of each patient’s baseline status
and health factors that might affect his or her response to antipsychotic therapy. Almost
every publication reviewed since 1999 concluded by calling for future research utilizing
the older population in high quality studies. This, however, did not occur.
Research Implications
Out of the frustrations of finding so few reliable studies investigating the older
population with schizophrenia arises opportunity. An intriguing possibility is that the
older population might be less susceptible to metabolic side effects than younger patients
with schizophrenia. Two studies indicated a lack of dyslipidemia in elderly patients
when similar studies indicated an increase in dyslipidemia in younger patients with
schizophrenia (Barak & Aizenberg, 2013; Finkel et al., 2009). Additional quality
research concerning safety profiles is needed in light of the high-risk potential of the
metabolic syndrome and cardiovascular disease currently associated with the elderly
population with schizophrenia.
Second, research noted elevated prolactin levels with FGA, as well as risperidone
and paliperidone (Tzimos et al., 2008; Table 2.2; Table 2.3). Younger patients manifest
breast tenderness, gynecomastia, and libido issues signaling elevated prolactin. However,
in elderly patients these cues are muted or nonexistent. With aging, a lower libido may
be considered normal and not questioned. The standard protocol for monitoring prolactin
is to assess “for cause” when symptoms are present. Without symptoms, these warning
signs would go unnoticed when levels are elevated. Hyperprolactinemia may initiate
calcium loss. With the higher prevalence of osteoporosis and hypocalcemia in the older
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population, a better understanding of the impact of elevated prolactin in older age is
important from both safety and good health standpoints.
Third, two studies examining sleep apnea and aging (Winkelman, 2001) and
severe obstructive sleep apnea and psychiatric patients (Martinez-Garcia et al., 2012)
indicated a high probability of increased cardiovascular death in the target patient
population. Although there are no studies that measure the relationship of sleep apnea to
antipsychotic medications, it is a potential concern because adding psychotropic
medication can impact the depth of sleep. Studies focusing on problem areas of
obstructive sleep apnea, respiratory issues, pneumonia, and cardiovascular issues are
critical as respiratory issues were a high-risk area identified in the correlation Table 2.3.
Fourth, the research most urgently needed would be pharmacology-based to
explore safety, tolerability, and efficacy of the newest second-generation antipsychotics
(SGA) such as iloperidone, lurasidone, asenapine, and paliperidone. The newest SGA
appear to have a promising profile, especially with the low affinity antagonism for
histaminic and muscarinic receptors reducing side effects to which elderly individuals are
particularly sensitive, including anticholinergic effects (Rado & Janicak, 2012).
Finally, more research funding for investigation of promising new antipsychotic
medications would be potentially beneficial. Some medications are not yet available in
the USA because they have not met criteria for FDA approval. Other medications may
have a broader research base because of the willingness of pharmaceutical companies to
fund the studies necessary to gain approval for specific medications. More independent
research about the multiple types of medications available is needed to help prescribers
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be as knowledgeable about the choices as possible to better guide decision-making for
each individual older patient with schizophrenia.
Practice Implications
With the increased knowledge base required for practice decisions, PMH-NPs
have a major role to play in treating patients with chronic severe mental illnesses that
persist into older age. Keeping abreast of new treatment, medications, and treatment
protocols with continuing education will continue to be a part of best practice
expectations. Maintaining records of patients’ lab work, current medications, and other
medical conditions at each visit is a cornerstone to quality care. Checking for TD and
EPS as well as side effects of the antipsychotic medications at each visit must be
included. Coordination with other disciplines that provide case management or providing
a holistic approach is ideal, but with funding often a problem for these services, PMHNPs can continue to advocate for patients as part of the best practice approach regardless
of the circumstances. Becoming aware of the lifestyle choices of each patient and
guiding them towards the healthiest options will be invaluable. Careful monitoring for
drug-to-drug interactions or symptoms of alcohol or substance abuse to minimize harm is
critical. Teaching and giving feedback for concerns of the patient and challenging
individuals to take their medication every day are important goals in helping patients
remain out of the hospital. Celebrating goals and achievements with the patient, as well
as mourning losses and failures, are ways of acknowledging the patient as a person. All
important parts of treating the whole patient, gaining trust, making a bond, and treating
the person must be included in care. The patients’ families should be incorporated as
partners in care and decision-making if possible and permitted by the patient. With the
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skills, training, and caring of the PMH-NP, the older patient with severe mental health
issues can find a competent professional for one-to-one treatment.
Policy Implications
The examination of literature for this project brought to light several policy
implications related to mental health care in the US. Foremost is the need for funding to
improve access to care. The Affordable Care Act (ACA) opened the door to many people
by offering healthcare to those who were previously uninsured. While still in the early
stages of implementation, the process was intended to be affordable and easier to
navigate with a greater transparency of services offered. Although Medicare covers
elderly adults with schizophrenia, changes to required insurance coverage may affect
access to mental health care in general. Several benefits afforded by the ACA have
significant implications for patients with chronic severe mental illnesses including
coverage for mental health, substance abuse, and pre-existing conditions. The ACA
requires that these benefits not be subject to greater restrictions or limitations than the
plan’s medical/surgical benefits (“Do marketplace,” n.d.). Closing the Medicare D
“donut hole” for medications have left some with even higher copayments. While
problems remain, PMH-NPs can use their influence to support policies that increase
access to affordable mental health care as well as to increase state and federal
appropriations for community mental health to permit case management, more clinics,
and more services for those who desperately need this assistance.
Second, the majority of funding for medication research comes from
pharmaceutical companies. Many of the studies are completed in fulfillment of FDA
requirements of trials required for protocols, with the goal of final drug approval for use
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in the US. These studies are usually 6 to 8 weeks, and rarely include the elderly
population. The newer drugs are also not included in the comparison studies. Financial
limitations drive the study designs, as the longer, RCT double blind placebo-controlled
studies are more costly. More funding must be allocated to independent researchers to
encourage more, less biased studies to explore the full range of drugs available to the
mental health population.
Finally, in order to best meet the expanding need for mental health care in the US,
PMH-NPs should be able to work within their full scope of practice. Removal of
restrictions on practice in all states would provide a bounty of highly skilled professionals
to care for the burgeoning older population, as well as the newly insured, to provide
competent care for all.

Active participation in professional organizations at state and

national levels, and taking leadership roles within the community and healthcare
organizations, can help remove barriers to practice and raise awareness of the ways in
which PMH-NPs can impact the healthcare system.
Conclusion
The key points of this project will help psychiatric practitioners be successful in
understanding the challenges and limitations of antipsychotic prescribing for older people
with schizophrenia, and offers recommendations for medication management of patients
who are living in the community. The goal of treatment with antipsychotic medication is
to achieve remission with fewer positive symptoms, reduced comorbid involvement,
better self-esteem, and the ability to remain independent. Dosage should be adjusted with
the individual patient’s profile, preference, response, and history in mind. By careful
monitoring of the metabolic indices, and maintaining a dialogue with the patient’s
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primary care provider or an independent practitioner, an active approach will minimize
side effect potentials of comorbid complications.
Primarily, practitioners must understand that regarding antipsychotic
medications, there is no right answer for what and how much to prescribe. While the
recommendations provided are a starting point, the best evidence to date involves
utilization of the provider’s best judgment on a case-by-case basis. Understanding the
patient as a person with unique preferences, personality, capabilities, and qualities is a
prime component in this process, as important as expertise in medical treatment and
psychopharmacology. When reaching a clinical decision, practitioners can use guidelines
but must generate a list of options based on best-practice choices distinct to each
individual. As new medication becomes available, the need for continuing education and
reassessment of knowledge and assumptions remains an ongoing process for all mental
health providers.
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Appendix A
Physiological Changes of Normal Aging by Body System
Cardiovascular
• A thickening of the interior lining of the heart muscle due to hypertrophy of
muscle fibers and narrowing of blood vessels causing arteriosclerotic streaks
and fibrous tissue to develop
• Loss of contractile efficiency due to muscle fibers replacement with
collagen or connective tissue calcium and decreased levels of circulating
catecholamines
• Decreased maximum heart rate and increased stroke volume with stress
• Peripheral vascular resistance increased 1% per year after age 60
• Cardiac output decreased one % a year
• Failed valves in legs and varicose veins result in venous stasis
• Higher blood pressure with longer time needed to return to baseline due to
decreased diameter of arteries and diminished stretch ability
• Decreased blood flow to the kidneys by 50% and 15-20% less to the brain
Hematologic
• Less sensitive baroreceptors
• Decreased serum albumin concentration
• Cell density of bone marrow decreased and cell proliferation diminished
Respiratory
• Loss of elasticity due to increased cross-linkage in collagen and elastin
fibers around alveolar sacs, causing decreased vital capacity
• Diminished chest wall compliance due to deformities of thorax, postural
changes, decreased strength of muscular skeletal system to assist in
respiration, degeneration of intervertebral disks, and increased anterior
posterior diameter of the chest
• Alveolar surface area collapse sooner on expiration, decreased by 20%,
which reduces O2 uptake by as much as 60% at age 85
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• Lung bases are less ventilated resulting in ineffective redistribution of blood
to compensate
• Oxygen levels fall and become worse when lying down resulting in
nocturnal hypoxemia (may cause confusion)
• Decreased number of cilia with an increase of mucous producing cells
• Less efficient in monitoring and controlling breathing
• Less sensitive to hypoxia
• History of smoking increased risks due to an increase in obstructive
components of lung function and decreased compliance of lung tissue through
deposits of foreign material
Gastrointestinal: Stomach
• Shrinking and inflammation of the inner lining of the stomach from
prolonged infection common in older adults
• Insufficient production of stomach acid
• Long-term use of pain medications causes stomach lining damage or H.
pylori
• Reduced colonic muscle tone and decreased colonic motor function
• Degeneration of smooth muscle lining the lower two thirds of the esophagus
resulting in delay in esophageal emptying, dilation of the esophagus, and
increased nonproductive contractions
• Oral issues include: loss of teeth, tongue papilla, reduced salivary ptyalin
and reduced or irregular esophageal peristalsis contributing to poor intake,
weight loss, and delayed emptying
Gastrointestinal: Liver
• Decreased ability of the liver to store Vitamin B12
• Reduced size and blood flow, with restricted oxygen diffusion
• Decreased ability to regenerate damaged liver cells
Gastrointestinal: Intestines
• Altered ability to absorb calcium, iron and lactose
• Weakness of intestinal wall and impaired intestinal muscle function
• Reduced peristalsis in the large intestine
Urinary: Renal
• Kidney mass is decreased by 25-30% with a decrease by 30-40% in
glomeruli by age 80, with an additional 30% sclerotic or nonfunctional
• Decrease in creatine clearance
• Total body water and lean body mass decrease
• Difficulty maintaining acid/base balance
• Hormones that regulate dehydration/hydration and the ability to conserve
sodium decline
• Decreased bladder capacity and residual urine
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• Nocturnal frequency of micturition and urinary incontinence due to: loss of
muscle tone that result in relaxation of perineal muscles (female); prostatic
hypertrophy, bladder diverticula and sphincter relaxation (male) may increase
UTI in both male and female
• In the elderly: low fluid intake, fluid loss from diarrhea, vomiting, shock due
to hemorrhage, acute or chronic cardiac failure, septicemia, toxicity from
antibiotics or injudicious use of diuretics can lead to renal ischemia and acute
renal failure
Endocrine
• Decreased insulin secretion and increased insulin resistance with decrease in
insulin receptor sites in the cell walls (Normal FBS levels rise 6-14mg per
deciliter every 10 yrs.)
• Decrease in aldosterone (30%) by age 70-80
• Cortisol decreased by 25% effecting anti-inflammatory and anti-allergy
effects
Neurological
• Decline in homeostatic mechanisms
• Intelligence remains unchanged
• Nerve impulses decrease conduction rate by 10% with decreasing neurons
and degenerating myelin sheath causing blurred signal and altered threshold
of organ response after a stress response
• Reduction in brain size by 20% with decrease in white matter by 11%
between 70 to 90 yrs. old and decrease in the number of synapses
• Decrease in dopamine content and receptor abundance
• Brain loses 100 gm. resulting in reduced oxygen consumption, less
intracellular energy produced, and glucose and cerebral blood flow reduced
• Depression is associated with declining levels of norepinephrine
• Declining dexterity and agility, difficulties with association, recall, and
retrieval, with decreased memory and cognitive abilities
•Decline in visual spatial abilities, both in perception and reproduction
•Problem-solving skills decline after 70+ yrs.
• Slowed processing reaction time
Immune
• Decreased production of thymic hormones
• Decreased levels of antibody response
• Diminished response to antigens
Musculoskeletal
• Loss of bone density: osteoblasts<osteoclasts
• Loss of muscle mass with decrease in amount and size of muscle fibers
(23% by age 80)
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• Peripheral motor neurons: decreased protein synthesis with thickening at the
myoneural junction and decreased acetylcholine level causing a general
decreased in movement, muscle stiffness, and slowness in initiation of
movement
• Joint changes include: erosion of the cartilaginous surface, degenerative
changes of soft tissue, calcification and ossification of ligaments, loss of
cartilage elasticity, and development of fibroblasts
• Increase in body fat
Reproductive: Female
• Decrease by 95% of levels of circulating estrogen with menopause
• Follicle stimulating hormone (FSH) and luteinizing hormone (LH) increase
• Atrophic changes in uterus and vagina, thinning uterine lining, decreased
elasticity and vaginal secretions with decreased libido and reduced or
anorgasmic
Reproductive: Male
• Decreased sperm production, by age 85, a 35% reduction of testosterone
and reduction in the size of the testes
• Increased irregular thickening with fibrous tissue causes enlarged prostate
• Decreasing testosterone levels may decrease libido, with a less intense
orgasm to erectile dysfunction
Sensory: Vision
• Corneal flattening reduces light admitted into the eye by one third. Pupil
size decreases by one third
• Transparency of the lens decreases with a yellowing occurs that alters colors
(Blue become more green, reds and oranges become more vivid)
• Diminished sensitivity of the retina reduces spatial discrimination,
white/black contrast, and flicker sensitivity. More time required to adapt from
dark to light
• The lens becomes less elastic decreasing focus and reducing visual acuity
• Arcussenilis may develop and lenses may cloud as a result of soluble
proteins forming cataracts
• Eyelids become thinner and wrinkled and skin folds from a loss of orbital fat
leading to ptosis; inversion or eversions of the lids are common as the
conjunctivae are thinner and more fragile
Sensory: Hearing
• Reduction in auditory acuity with 10dB sensitivity loss for each decade
beginning at age 60, male>female
• Degeneration of the vestibular apparatus
• Stiffness and less sensitive middle ear and tympanic membrane
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• Reduction in hearing acuity of one-third the older population related to
cerumen, antibiotics, or diuretics
Sensory: Olfactory, Taste, and Touch
• Decrease in receptors beginning at age 50. By age 80, smell reduced 50%
• Atrophy of tongue and sensory receptors diminish taste
• Decrease in touch receptors and response to painful stimuli
Skin & Hair
• Thinning of the area between the dermis and epidermis by two %, decrease
in elastin and collagen with a reduction in the size of skin cells and a
decreased ability to retain moisture
• Thinning of the subcutaneous layer of fat under skin
• Decrease in melanin and number of hair follicles with loss of pigment and
slower growth
• More facial hair with decreasing estrogen levels (female)
• Increased hair growth in nose, ears, and eyebrows (male)
• Less active sebaceous and sweat glands
Note. Adapted from Pathophysiology: Adaptions and alterations in function (3rd ed.) by
G. McDaniel, pp. 156-173. Copyright 1992 by Courier Book Company.
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